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ABSTRACT 
UNIVERSITY OF TURKU 
Department of Chemistry/Faculty of Mathematics and Natural Sciences 
 
JADHAV, SATISH GANPAT: Covalent conjugates of therapeutic oligonucleotides for 
in vivo targeting 
 
Doctoral thesis, 115 P.  
Laboratory of Organic Chemistry and Chemical Biology 
September 2016 
 
Over last few years, the development of oligonucleotide based therapeutics (antisense, 
siRNA, antagomirs) have received much interest as a novel class of drugs for the 
treatment of many diseases. Cell/organ specific targeting of oligonucleotides by covalent 
conjugation has become a promising approach for developing therapeutic RNAs. The 
major obstacle in the use of therapeutic RNAs is the cell/organ specific targeting and 
internalization of the large anionic oligonucleotides across the plasma membrane of the 
cells.  
This thesis focuses on the synthesis of different receptor specific ligand conjugates of 
oligonucleotides. The oligonucleotides are conjugated with different targeting ligands 
such as i) Galactose cluster, ii) Hyaluronic acid hexamer, and iii) Bisphosphonate 
derivative. Multi-galactose-conjugated 2’-O-methyl oligoribonucleotides showed 
remarkable galactose-dependent liver targeting of the conjugates monitored by in vivo 
positron emission tomography (PET) imaging in healthy rats. Hyaluronic acid 
hexasaccharide oligonucleotide were conjugated efficiently by using copper free click 
reaction (SPAAC conjugation approach) and also studied by in vivo PET imaging in 
myocardial infarction rat models. Bone targeting bisphosphonate oligonucleotide 
conjugates were prepared by SPAAC conjugation approach and in vivo PET imaging 
exhibited enriched radioactivity accumulation to bones in healthy rats. Additionally, a 
straightforward method was described for the synthesis of solid supported porphyrin 
biomolecule conjugates. The whole-body distribution of the conjugates in rats was 
monitored by PET. These oligonucleotide conjugates were efficiently labeled by 
complexing 68Ga, with a 3´-terminal 1,4,7-triazacyclononane-1,4,7-triyl)triacetic acid 
(NOTA) ligand. This allowed in vivo quantification of oligonucleotide pharmacokinetics 
and bio-distribution data in rats.  
Key words: Galactose cluster, Hyaluronic acid, Bis(phosphonate), 68Ga-labeled 
oligonucleotides, in vivo PET imaging.  
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ABBREVIATIONS 
A adenosine 
Ac  acetyl 
AcOH  acetic acid 
ASO    antisense oligonucleotide 
ASGPR     asialoglycoprotein receptor 
BAIB     (diacetoxyiodo)benzene  
BP  bisphosphonate  
Bz  benzoyl 
Bn  benzyl 
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dsRNA  double-stranded RNA 
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G       guanosine 
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PET   positron emission tomography  
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RISC   RNA-induced silencing complex 
RNA     ribonucleic acid 
RNAi  RNA interference 
RNase   ribonuclease 
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1. INTRODUCTION 
1.1 RNA as drug target 
 Structure of RNA 
RNA, as DNA, consists of a long polynucleotide chain linked via phosphodiester bonds 
(Fig. 1). The structure of the sugar moiety is, however, different, RNA chain contains β-
D-ribofuranosyl residues instead of 2´-deoxy-β-D-erythro-pentofuranosyl groups of 
DNA. RNA contains adenine, cytosine and guanine bases, like DNA, but thymine base 
of DNA is replaced by uracil. Unlike DNA, RNA is more often found in nature as a 
single stranded molecule, and it may fold onto itself and form hairpin loops via 
intramolecular hydrogen bonding between complementary bases. However, RNA can 

























































RNA: X= OH, Uridine: R = H
DNA: X= H, Thymidine: R= Me
O
 
Figure 1. The structure of RNA and DNA and Watson-Crick base pairing. 
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 Biological functions of RNA (drug target) 
RNAs has long been dominated by central dogma view in molecular biology.1, 2 In 
general, messenger RNAs (mRNAs) transcript instructions from DNA in the form of 
specific base sequences, and mediate the information to ribosomes, nucleoprotein 
complexes where the protein synthesis takes place. Two other RNAs, viz. ribosomal 
RNAs (rRNAs) forming the core structural framework of this protein synthesis machine, 
and transfer RNAs (tRNAs) carrying amino acids to this machinery, participate in the 
process. In fact the primary transcript of mRNA, called pre-mRNA, is longer than the 
mature mRNA containing non-coding sequences, introns, between the coding regions, 
exons. The non-coding introns are removed and exons relegated by splicing reactions 
catalyzed by spliceosome, a protein complex of short RNA-oligonucleotides. 
The RNAs that are used for other purposes than protein synthesis are called as noncoding 
RNAs. Numerous noncoding RNAs are responsible for regulation of gene expression,3, 
4  i. e. protein production from coding genes, which is the foundation of cellular structure 
and physiology. In prokaryotic cells (e.g. bacteria), small antisense RNAs regulate the 
gene activities by binding to target mRNA. In addition, the so-called riboswitches also 
function as regulatory domains in longer mRNAs, via binding to small molecule 
nucleotides or amino acids.5  In eukaryotic cells, large number of small RNAs exert 
interfering properties as well. Among those, miRNAs are the most studied regulatory 
noncoding RNAs.6 Generally, double stranded miRNAs of about 22 nucleotide long 
sequences are produced from long single stranded miRNA precursor which contains 
hairpin structures. Double stranded miRNAs incorporate into proteins of Argonaut 
family, bind complementary mRNAs and inhibit stability or translation. First one of the 
strands is cleaved by Argonaut 2, and the remaining one recognizes mRNA. Several 
hundreds of miRNAs, present in animals and plants can regulate the activity of up to one 
third of coding genes. Another well studied noncoding RNA is the small interfering RNA 
(siRNA).7,8 SiRNAs are similar to miRNAs in terms of length and also association with 
Argonaut protein. Essentially, siRNAs can be produced from any copied region of the 
genome and it acts directly upon that particular location, hence siRNAs are found in 
those cells where self-regulatory process by RNAi is underway. A major function of 
some of the noncoding RNAs is to protect cells against viruses, and transposons.  In 
response to viral infections, cells produce complementary siRNAs to viral mRNAs and 
also inhibits transposons and repeat sequences in similar manner. Similarly, in animals 
the genome stability is protected by Piwi-associated RNAs (piRNAs).9  
1.2 Therapeutic oligonucleotides 
Eventually, the question arose can we stop the protein synthesis at the level of mRNA? 
Indeed, in 1978 Zamecnik and Stephenson10 studied inhibition of Rous sarcoma virus 
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replication by using specific oligonucleotides (ONs). Later, there has been numerous 
studies that evidenced ONs to target mRNA in a highly selective manner. In principle, 
any 17 nucleotides sequence occurs only once in human genome (109-1010). 
Accordingly, any mRNA can in principle be entirely selectively arrested by a 
complementary 17-mer ON.11 This prevents the hybridization with rRNA and stops 
disease causing protein being synthesized. Strategies that target mRNA include the use 
of single stranded antisense ONs, double stranded ONs (siRNA,) (Fig. 2), and nucleic 
acid enzymes (ribozymes and DNAzymes). In general, antisense ON mechanisms can 
be based on two main ways: (i) interfering in RNA’s function without promoting RNA’s 
degradation and (ii) promoting RNA’s degradation. In addition, 70% of the human genes 
undergoes alternative splicing, and splicing errors because of mutations are responsible 
for about 50% of gene causing diseases. Antisense ON has emerged as a tool for 




















Figure 2. Therapeutic ONs mechanism of actions13: 1) antisense ONs, and splice switching ONs, 
2) siRNA, and 3) antagomirs.  
 Antisense oligonucleotides (ASO) 
Chemically modified antisense ONs comprise 12-25 nucleotides long single stranded 
DNA analog chains, designed to be complementary to target mRNA. An antisense ON 
imparts specific binding to mRNA by Watson-Crick base-pairing .14, 15, 16, 17 Unlike small 
molecule drugs, which act as  antagonists and alter biological processes by binding to 
target proteins, receptors and enzymes, antisense ONs bind complementary to the 
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specific sequences of nucleotides of the target mRNAs. There are two cellular 
mechanisms that antisense ONs utilize: activation of RNase H by the antisense ON 
leading to degradation of target mRNA and steric blocking of mRNAs by hybridized 
antisense ON. Formation of DNA-RNA hybrid duplex recruits the RNase H enzyme 
present in mammalian cells, which recognizes hybrid duplex substrate and cleaves at the 
center of target mRNA, retaining DNA intact.18 Antisense ONs drug can work in both 
the nucleus and cytosol, due to presence of RNase H enzymes in both cellular 
compartments. 
Antisense ONs that do not activate RNase H mediated mRNA degradation, but can act 
as steric blocks to mRNAs/pre-mRNAs without its degradation, also can be able to 
induce modulation of genes.19 Steric-blocking ON drug can modulate splicing of target 
pre-mRNA, and also it can block the translation of mRNA. Particularly, splice switching 
oligos (SSOs) have been emerging in clinical studies against rare genetic diseases such 
as Duchenne muscular dystrophy and spinal muscular atropy.12 SSOs can block the 
spliceosome at the splice site on targeted pre-mRNA and modulate pre-mRNA. In 
addition, it can also be used to correct defective pre-mRNA by exon skipping and restore 
the synthesis of beneficial protein. 
 Small interfering RNAs (siRNA) 
RNA interference (RNAi) was evidenced very first in Caenorhabditis elegans 
nematode.20 The long double stranded RNAs were exogenously delivered. These 
outcome very efficient and specific silencing of expression of a gene by prompting 
cleavage of target mRNA. Usually, siRNAs are of about 21-23 nucleotides long, 
duplexes, with two base 3’-overhang and 5’-phsophate group. In the cytoplasm of cells, 
siRNAs incorporate into an Argonaut 2 (Ago2) protein complex, the RNA-induced-
silencing complex (RISC). Because of the asymmetry in thermodynamic stabilities 
(predicted) of the two termini of the siRNA duplex, RISC machinery component selects 
the antisense strand (guide strand), and cleaves the sense strand (non-guide strand). The 
antisense stand serves as a template for mRNA recognition and binds complementary to 
target mRNA. In later step, siRNA-mRNA duplex is cleaved between 10 and 11 
nucleotides from the 5’-end of antisense strand by the same Ago2.21  
 Antagomirs (anti-miRs) 
It has been found that dysregulation of miRNAs has been responsible for variety of 
disorders, such as myocardial diseases,22 neurological disorders,23 different types of 
cancers,24 and viral infections.25 Antagomir is an antisense ON targeted towards miRNA 
to overcome the inhibition of protein synthesis by miRNA.26 Hence, antagomirs have 
been emerging as a promising approach for treatment of diseases caused by 
dysregulation of miRNA expression. The miRNA biogenesis encompasses transcription 
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of miRNA genes in nucleus by RNA polymerase II (Pol II), giving primary miRNA 
transcripts (primiRNAs) that are then cleaved in nucleus by a complex of Drosha and 
DGCR8. The resulting precursor miRNA hairpin (pre-miRNA) is exported into cytosol 
through Exportin-5 and further processed by the RNase Dicer to an intermediate miRNA 
duplex. The leading strand is then loaded into the (mi)RNA-induced silencing complex 
(mi)RISC, whereas the second strand is subjected to degradation. The strand selection 
depends on the thermodynamic characteristics of the miRNA duplex. The (mi)RISC 
complex is guided to target mRNAs sequences that are located within the 3′ untranslated 
regions (3′UTRs) of the mRNA. Following these reactions, the mRNA is targeted by 
translational repression and/or degradation. Unlike siRNAs pathway, which requires 
perfect complementarity to target mRNA, miRNA can bind with mismatches. In general, 
chemically modified antagomirs are designed to be as steric blocking ONs, it binds fully 
complementary to seed region of the target miRNA instead of mRNA. Hence, loading 
of miRNA in to RISC complex and subsequent binding to mRNA can be prevented, 
resulting in blocking of miRNA functions. 27  
1.3 Stability 
Internucleotide phosphodiester linkages in native DNA and RNA are too unstable in 
serum and in mammalian cells due to phosphodiester cleavage by exo- and 
endonucleases. Chemical modifications are required to improve their nuclease 
stability. One obvious way is to modify the internucleosidic phosphodiester linkage. 
The oldest and most extensively studied modification is substitution of one of the non-
bridging oxygen atoms with sulfur, giving phosphorothioates that are sufficiently 
stable against nucleases (Fig 3).28 In addition to phosphorothioates, boranophosphate, 
methylphosphonate, and phosphoramidate, linkages also enhance nuclease 
resistance.29 Boranophosphate modification is even more stabilizing than 
phosphorothioate,30 unfortunately, their chemical synthesis is difficult. Two heavily 
modified uncharged DNA analogs, peptide nucleic acid (PNA) and morpholino 
oligonucleotides (PMO) deserve special attention. PNA has a peptide-like backbone 
composed of neutral N-(2-aminoethyl)glycin units.31 PMO is, in turn, composed of 6-
hydroxymethylmorpholine units that bear a nucleobase at C2 and are linked to each 
other via phosphoamidate bonds.32 Both oligomers show excellent nuclease 
stability.33,34 Moderate, but not necessarily sufficient, nuclease stability is also 
achieved by sugar moiety modifications, such as 2´-O-methyl (2´-O-Me-RNA), 35 2´-
O-(2-methoxyethyl) (2´-O-MOE-RNA),36 2´-deoxy-2´-fluoro (2´-F-RNA),34 4´-C-
aminomethyl-2´-O-methyl37 and 4´-thio (4´-S-RNA)38 modifications of 
ribonucleosides, and 2´-fluoro substitution of arabinonucleosides (2´-F-ANA) (Fig. 
4).39 Furthermore, 2’-4’ bridged analogs, LNA, ENA and their congeners, are 
reasonably stable towards nucleases.40 Besides these 5-membered ring mimics, 
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expanded ring system containing cyclohexene nucleic acid (CeNA), and oxepane 
nucleic acids (ONA) also show enhanced nuclease resistance.41,42 
 
Figure 3. Chemical modifications of backbone linkages 
1.4 Affinity & turnover 
Phosphorothioate ONs exhibit besides good nuclease stability another useful 
characteristic; they activate RNase H.28 RNaseH enzymes present in mammalian cells, 
recognize DNA-RNA hybrid duplex and cleave only RNA, retaining DNA intact.43 
Accordingly, the action of phosphorothioate ONs is catalytic and, hence, their somewhat 
less efficient hybridization compared to native DNA ONs is not detrimental.  Only few 
antisense ON candidates have the same property. Boranophosphate ONs, 2´-F-ANA, 
CeNA and ONA have been shown to activate RNase H.29, 30, 40 Although most antisense 
ON candidates do not activate RNase H, they still may be serious drug candidates, 
providing the affinity to RNA is high. These include PNA, PMO and 3´-phosphoamidate 
ONs. Similarly, sugar 2’-O modifications such as 2’-O-Me, 2’-F, and 2’-MOE that prefer 
the C3’-endo ring-puckering and, hence, enhances binding to RNA,44,45,36  While, 2’F-
ANA analog is structurally a DNA mimic, it still exhibits increased hybridization affinity 
(1.2oC per insert) to complementary RNA. This together with the ability to activate 
RNase H.46 makes it a promising antisense ON candidate. 
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Figure 4. Chemical modifications of sugar units 
LNA and its congeners, although unable to activate RNaseH, also deserves special 
attention, owing to excellent hybridization properties. LNA , units having a rigid N-type 
conformation impressively enhances the  affinity to RNA, ~5.6oC per insert.47,48,49, 
Numerous bicyclic  2’-4’ bridged analogs of LNA have  been synthesized The best 
known examples include 2’-O,4’-C constrained ethyl BNA (cEt-BNA),50 2´-O,4´-C-
ethylene nucleic acid (ENA),51 N-MeO-amino BNA, 2’-4’ BNANC [NMe].52 Structurally 
constrained bicyclic and tricyclic analogs, bicyclo[3.1.0]hexane (MC)53 and Tricyclo-
DNA (tc-DNA),54  modifications also markedly increase the binding affinity  to 
complementary ONs. CeNA,55 HNA and ANA56 analogs bind tightly to complementary 
RNA strand. 
1.5 Pharmacokinetics and bio-distribution of oligonucleotide 
drugs 
ON drugs can be administered systemically via two primary routes, either subcutaneous 
(SC) injection or intravenous (IV) infusion. During systemic SC or IV administration, 
PS-modified antisense ONs are quickly transferred through blood circulation into tissues 
(minutes to hour). As ONs drug start to get into tissues (minutes to hour), the plasma 
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concentration decreases exponentially followed by slower terminal eliminations (half-
life about weeks). As compared to IV infusion, peak plasma concentration are about 3-
to 10 times lower in case of SC injection, most likely because of time required to absorb 
ON drugs in to blood circulation from the site of SC injection, and their rapid tissue 
distribution from blood circulation. However, during SC injection, plasma concentration 
decreases gradually as compared to IV infusion.57 Pharmacokinetic properties of 
antisense ONs has been observed to be alike across species and gender.58 Unmodified 
charged ONs (including unmodified siRNA) as well as neutral ONs (PNA, PMOs) 
possess low binding affinity to cellular proteins in  plasma; they are metabolized in blood 
or rapidly cleared by glomerulus in kidney, and renal excreted, resulting in low or none 
tissue uptake. By contrast, PS-modified ONs show high binding affinity to plasma 
proteins, and albumin. This increases in vivo circulation time, results in improved tissue 
bio-distribution and cell uptake. Systemically administered antisense ONs are naturally 
highly distributed over tissues such as liver, kidney, spleen, bone marrow, adipocytes, 
and lymph nodes.59 In general, across all animal species, antisense ONs distributes 
broadly into many tissue types, except central nervous system, because of inability to 
pass blood–brain barrier (BBB). However, central nervous system (CNS) targeting 
antisense ONs drug has also been administered via intrathecal i.e. direct injection in to 
subarachnoid spaces, where ONs drug can be targeted to brain through cerebrospinal 
fluid (CSF).58  
1.6 Cellular Uptake 
Delivering systemically therapeutic ONs into cytoplasm of cells is the key hurdle in 
development of ON therapeutics. Because of the large, hydrophilic, and anionic nature 
of the ON molecules, penetration across the cell membrane barrier is difficult. It is also 
worth noting that the cellular uptake cannot be simply increased by using charge neutral 
modified ONs.  Methyl phosphonates and PNA analogues, for instance, do not show 
enhanced cellular uptake.60 Usually ON drugs can be internalized into cells through some 
form of endocytosis,61 which involves mainly cell surface receptor mediated endocytosis 
(Fig. 5) ON binds to cell surface receptors and enters by forming vesicles. Some of the 
vesicles first traffic in to early endosomes, and few of those endosomes recycles 
receptor–oligo complex back on the cell surface. In other cases, vesicles enter in to low 
pH late endosomes, which later leads to lysosomes, where the cargo is degraded. 
However, due to intracellular dynamic processes, tiny amount of ONs leaks in to 
cytoplasm from disrupting endosomes; this is the only pharmacologically active portion 
of ONs usually being utilized. Single stranded P-S modified ONs are internalized more 
efficiently into hepatocyte cells most likely binding to surface proteins and 
endocytosis.28 In general, transport of ONs drugs through cell membrane and endosomal 
trapping of nonproductive ONs remains the biggest issue in cellular uptake.  
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Figure 5. Biological barriers in delivering ON drugs in to cells 67(Adapted from Elsevier with 
permission) 
1.7 Targeting by covalent conjugation 
It would naturally be highly desirable to target ON drugs to specific tissues/organs and 
facilitate cellular uptake for pharmacological activity. There have been two types of 
strategies being used for delivering ON drugs. Covalently attached ONs and non-
covalently bound ONs complexes or different kind of advanced formulation techniques. 
These non-covalent ONs complexes applications are discussed in more detailed 
elsewhere. 62, 63, 64, 65 
Recently, many approaches are being developed, based on covalent conjugation of ON 
with receptor targeting ligands such as lipids, peptides, carbohydrates, small molecules, 
aptamers and cell penetrating peptides (CPPs).66, 67, 68Covalently linked conjugates are 
molecularly well defined, and often quality of the ON conjugates can be easily monitored 
and controlled by using standard analytical techniques. In general, covalent ONs 
conjugates are physically more stable and possess broad tissue distribution space as 
compared to formulation or nano particles or polymer based delivery techniques. 
However, inside the cell covalently attached ligands should be inert enough to avoid 
interference in binding of ONs to target mRNAs, as well as in the post binding events 
like RNase H or the RNAi machineries. Generally, conjugating small ligand at 3’ or 5’- 
terminus in single stranded ONs is better tolerated than modifications in siRNA.69 
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Inevitably, the 5’-terminus of the antisense strand in siRNA is required to be 
phosphorylated in order to being recognized by RISC. Hence, ligands cannot be attached 
to 5’-terminus of antisense strand in siRNA.70 Commonly used stable irreversible 
linkages such as, amide, ester, thioether, thiol-maleimide, and triazole has been utilized 
in synthesis of covalent ON conjugates. However, bio-reversible linkage such as 
disulfide may provide additional benefits in pharmacological activity, since after 
entering conjugates into cell cytoplasm, disulfide bond is potentially reduced by 
cytosolic environment and may liberate intact ON drugs.71 In addition, acid labile 
linkages such as β-thiopropionate have also been used. These are aimed at being cleaved 
at low pH endosomal conditions.72  
Essentially, existence of a cell-specific receptor, density of the receptors on the targeted 
cells, the ligand selectivity/specificity and their binding affinity are crucial for cell 
specific ONs delivery. Intrinsic affinity of P-S modified ONs and phosphodiester linked 
ONs to certain cell surface receptors may alter the targeting properties, and cellular 
uptake.67 
 Lipid-oligonucleotide conjugates 
Lipid molecules are hydrophobic in nature, they constitute structural component of cell 
membrane as a hydrophobic interior of the phospholipid bilayers. Conjugates of lipids 
with ONs do not only minimize the charge repulsion effect but they also bind sufficiently 
to lipoproteins, which may increase in vivo circulation time and possibly lead to desired 
tissue distribution and enhanced cellular uptake. Very first example of using systemic 
administration route is the cholesterol-siRNA conjugates that showed efficient targeting 
of apolipoprotein B mRNA via RNAi by intravenous injection in mice (Fig. 6).73, 74 These 
conjugates interact and bind with different lipoprotein particles and lipoprotein receptors 
in blood circulation. Pre-complexed high density lipoproteins with ON conjugates target 
to liver, kidney, and steroidogenic organs, via SR-BI receptors mediated endocytosis, 
while low density lipoproteins-ON conjugate complex facilitates uptake predominantly 
into liver hepatocytes by targeting LDL-receptors mediated endocytosis.75   
In addition, by intrathecal administration, i.e. direct infusion of cholesterol-siRNA 
conjugate into central nervous system (CNS), targeting of CNS disorders such as 
Huntington disease has been achieved and inhibition of the neurodegenerative disease 
causing gene via RNAi has been demonstrated.76 Since, LDR receptors are present in 
brain cells, cholesterol-siRNA conjugates become internalized via receptor mediated 
endocytosis. In most of the CNS targeting ON conjugates, cholesterol has been tethered 
covalently to 3’ terminus of the passenger strand of siRNA via the hydroxy prolinol 
strategy. Interestingly, use of a cleavable disulfide linker showed two times higher 
efficiency in silencing of CNPase (2′, 3′-cyclic nucleotide 3′-phosphodiesterase) mRNA 
in oligodendrocytes.77 Similarly, cholesterol-antagomir conjugates also have been 
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utilized in miRNAs based targeting approach. Covalent adding of cholesterol unit to the 
3’-end of anti-miR-122 (2’-O-Me) has been utilized for liver specific inhibition of miR-
122 in mice.78 In another study, cholesterol -anti-miR-10b conjugate has been 
demonstrated for targeting the breast cancer metastasis in mouse mammary tumor 
models, resulting in efficient silencing of miR-10b in vivo.79 In addition, cholesterol 
conjugation  has been utilized in antisense ONs; hepatitis C virus (HCV) RNA targeting 
17-mer (2’-O-Me) antisense-ONs were prepared by conjugating cholesterol and 
octadecanol to the 3’ end of ONs by click chemistry and both cholesterol-ONs and 
octadecanol-ONs, when tested in cultured human hepatic cells, exhibited dose dependent 
reduction of HCV translation.80 Furthermore, 5’-palmitic acid conjugates of a 13-mer 3’-
thiophosphoramidate bind to the active site of human telomerase. This has been under 
evaluation for clinical trial II as an anticancer agent. 81  
 
Figure 6. siRNA conjugates with (i) cholesterol, (ii) fatty acids, (iii) vitamins, and (iv) bile acid  
Besides cholesterol, other lipophilic moieties such as long chain fatty acids and bile acid 
have been conjugated to 3’-end passenger strand of siRNA. These studies reveal that 
conjugates with longer alkyl chain (C18) possess high binding affinity to lipoprotein 
particles and result in efficient gene silencing compared to shorter alkyl chains.75 The 
fat-soluble hydrophobic vitamins, such as α-tocopherol, have their own physiological 
pathway to most of the organs. α-Tocopherol conjugated to 5’-end of the guide strand of 
siRNA has been used for silencing apoB. After entering cells, α-tocopherol moiety was 
cleaved by Dicer, liberating active siRNA and resulting in efficient gene inhibition in 
liver without triggering immune response.82 Complexing of high density lipoprotein 
(HDL) with α-tocopherol-siRNA conjugate facilitates uptake into brain, as demonstrated 
via intracerebroventricular (ICV) infusion.83  Other studies demonstrate that the vitamin 
A (retinol)-liposomes facilitate the siRNA uptake into hepatic stellate cells.84 Vitamin A 
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most likely binds to retinol-binding proteins and mediates receptor mediated 
internalization into these cells.  
 Small molecule–oligonucleotide conjugates 
Small molecule-ON conjugates also have been recently explored for targeted receptor-
specific delivery approach. Trivalent anisamide conjugate of a splice switching antisense 
oligonucleotide (SSO), which target a sigma receptor, when tested by their ability to 
modify splicing of a reporter gene (luciferase) in tumor cells in culture, displayed 
enhanced cellular uptake and was markedly more effective than an unconjugated SSO 
or the monovalent conjugate (Fig. 7).85Another example is offered by folic acid that 
binds to folate receptors overexpressed in many human cancer tumors. Conjugates of 
folic acid with siRNA and also with other therapeutic biomolecules have been targeted 
via receptor mediated endocytosis to enhance cellular uptake and pharmacological 
effect.86 In another study, folic acid-PEG-siRNA conjugate in cell culture showed to be 
internalized into folic acid receptor expressing cells, but it did not silence the reporter 
genes. However, transfection along with a structurally defined polycation resulted in 
specific gene silencing.87 By a similar approach, neuronal and immune cells have 
recently been targeted by anandamide (arachidonoylethanolamin)-siRNA conjugates.88  
Anandamide (cis-configuration) is a ligand for cannabinoid receptors present on 
neuronal and immune cells. Anandamide-siRNA conjugates are most likely taken up via 
receptor mediated endocytosis and they show similar silencing effect as standard 
cationic transfection reagents. In addition, dendritic siRNA nanostructures were 
covalently conjugated with anandamide moiety by copper catalyzed click reaction.89 
Interestingly, single anandamide moiety was able to internalize about nine siRNA 
duplexes and elicited efficient RNAi in neural stem cells and also exhibited suppression 
of viral titer of the rabies virus (RABV) in neurons. 




























































































Figure 7. Small molecule-siRNA conjugates  
 Peptide-oligonucleotide conjugates 
Two types of peptides, cell penetrating peptides (CPP) and receptor targeting peptides, 
have been used for delivery of ON drugs into cells (Fig. 8). Numerous in vitro studies 
on peptide conjugates of ONs and PNAs are available, the in vivo data still is scarce.90 
Cell penetrating peptides are typically 10-30 residues long, positively charged peptides 
that contain highly basic amino acids. When conjugated with neutral ONs, such as PNA 
and PMO, they efficiently enhanced transport across the cellular membrane, most likely 
via receptor mediated endocytosis, although precise mechanism is still an open question. 
In an early study, a conjugate of 21-mer PNA and transportan (a 27 amino acid-long 
CPP) downregulated galanin type 1 receptor in the rat spinal cord when administered 
intrathecally.91 Most promising results were obtained with Duchenne muscular 
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dystrophy (DMD) disease on using PNA or morpholino (neutral) antisense oligomers 
for splice-switching (correcting out-of-frame mutations).92  
 
Figure 8. Cell penetrating petide conjugates and receptor targeting peptide conjugates. 
Systemic delivery of a conjugate of morpholino oligomer (PMO) and a CPP targeted 
towards a mutated dystrophin exon restored dystrophin to almost normal levels in the 
cardiac and skeletal muscles in dystrophic mdx mouse, utrophin-dystrophin double-
knockout mice, and CXMD dogs, as well as in DMD patients in clinical trials.93 Another 
study showed that addition of a muscular-targeting heptapeptide in the construct 
enhanced the efficiency. The conjugate restored uniform dystrophin protein expression 
in multiple peripheral muscle groups, yielding functional correction and improvement 
of the mdx dystrophic mice phenotype.94 By peptide sequence optimization a peptide-
PMO conjugate was obtained that showed highly efficient exon skipping and dystrophin 
production in mdx mice, leading to >50% of the normal level of dystrophin in heart. The 
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enhanced activity was partly explained by more efficient nuclear delivery.95 As an 
example of usefulness of targeting peptides, integrin receptors have been targeted by 
Arg-Gly-Asp (RGD) conjugates, but so far only cell culture results are available. Mono- 
and multi-valent versions of the cyclic RGD peptide that binds selectively to the ανβ3 
integrin that is over-expressed in angiogenic vasculature and in certain tumors, have been 
prepared and receptor-mediated uptake demonstrated in cell lines.96 Although cellular 
uptake level seemed equal for bi-, tri-, and tetravalent –RGD-siRNA conjugates, tri- or 
tetra-valent cluster was necessary for significant pharmacological activity.  Similarly, 
gastrin-releasing peptide receptor (GRPR), a member of the G protein-coupled receptor 
superfamily, has been targeted in a cell culture by a bombesin conjugate of splice-
shifting 2´-O-Me phosphorothioate ON and receptor-mediated uptake.97 
 Aptamer- CpG- oligonucleotide conjugates 
Aptamers are single stranded tertiary structures of ONs that possess binding properties 
to specific target receptors. These ONs are selected from screening pools of ONs via 
Systemic Evolution of Ligands by Exponential Enrichment (SELEX) method.98 In 
addition to binding as inhibitors, aptamers can mediate receptor mediated endocytic 
delivery of ONs drugs.99 One of the promising targets has been targeting of prostate-
specific membrane antigen (PSMA), which is overexpressed in prostate cancer cells.98 
Aptamer conjugated with siRNA, has been tested in cells expressing PSMA. The 
conjugate was selectively taken up into cells and processed by Dicer, as demonstrated 
by inhibition of target mRNA and consequent cell death. These conjugates specifically 
inhibit tumor growth and mediate tumor regression in a xenograft model of prostate 
cancer.100 Furthermore, the structurally optimized aptamer-siRNA conjugates employed 
via systemic administration exhibit prominent regression of PSMA-expressing tumors. 
Interestingly, introducing polyethylene glycol moiety showed enhancement in anti-
tumor activity, which most likely results from increased circulation half-life in blood.101 
Similarly, there has been development of anti-HIV gp120 aptamer mediated siRNA 
delivery. An aptamer with high binding affinity to the HIV-1 envelope (gp120) protein 
and virus neutralization, when attached to siRNA showed that siRNA triggers sequence-
specific degradation of HIV RNAs. The aptamer-siRNA conjugate resulted in more 
prominent inhibition and promising antiviral activity as compared to the aptamer 
alone.102 
Toll like receptors also has been targeted for (TLR9) agonist– mediated delivery of ONs 
drugs.103 siRNA linked to a CpG ON agonist of toll-like receptor (TLR)9 was shown to 
target and silence genes in TLR9+ myeloid cells and B cells. 104  Conjugates of siRNA-
TLR9 agonist, targeting immune suppressor gene Stat3, demonstrated internalization in 
tumor-associated dendritic cells, macrophages and B cells. In general, silencing of Stat3 
activates tumor-associated immune cells and as a result antitumor immune responses.  
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 Carbohydrates-oligonucleotide conjugates 
Carbohydrates play numerous pivotal roles in cellular processes via carbohydrate-
protein and carbohydrate-carbohydrate interactions.105,106 Lectins are the cell surface 
carbohydrate binding proteins present in most of the living organisms. Although 
carbohydrates lectin binding on the cell surface usually is specific for a certain 
monosaccharide, the interactions with monomeric sugars are low affinity interactions (at 
millimolar level). To ensure high affinity binding, carbohydrate epitopes and lectins are 
in vivo oriented in such a manner that multiple binding events can occur simultaneously 
(Fig. 9). In other words, the lack of strength of an individual interaction is compensated 
via multivalency. Most of naturally occurring glycoconjugates and their synthetic 
analogues show enhancement in affinity per a mole of saccharide compared to the 




















Figure 9. Design of multivalent ASGPR receptor specific Galactose/GalNAc ligands.108 
A most successful emerging approach is targeting of asialoglycoprotein receptors 
(ASGPR) in liver.109 ASGPR is abundantly expressed only by parenchymal hepatocytes 
(~500 000 copies/cell). It is a type II transmembrane glycoprotein (~40 KD) regulating 
the homeostasis of serum glycoprotein levels by binding and uptake of galactose 
terminated glycoprotein. The human ASGPR consists of two subunits, H1 and H2, with 
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the H1 subunit mediating Ca2+ dependent galactose or N-acetylgalactosamine (GalNAc) 
recognition (Fig. 9). ASGPR mediates the endocytosis of bound ligands, such as 
galactose or GalNAc, by internalization via clathrin-coated pits endocytosis. In case the 
ligand becomes released into endosomal compartments, the lectin receptor is recycled to 
cell surface. There has been wide interest in development of carbohydrate-ON 
conjugates for tissue specific targeted delivery and to facilitate the cellular uptake 
through receptor mediated endocytosis.110, 111   
Trivalent GalNAc cluster was in early studies covalently conjugated with 
methylphosphonate and phosphorothioate ODN via a neoglycopeptide linker. These 
conjugates were tested in rats for in vivo biodistribution and metabolism. The results 
showed 70% improved liver uptake of the conjugates.112,113 Similarly, Biessen et al. 
demonstrated that the galactose tetrantennary lysine-based cluster conjugated to a 20-
mer 32P-ODN showed in vivo four-fold increase in parenchymal liver cells uptake 
compared to unconjugated ODN.114,115 Monogalactosylated-PEG-33P-ODN 
conjugates with an acid labile ester linkage of β-thiopropionate also has been shown 
to enhance uptake by hepatocytes.116 In a very similar approach, siRNA has been 
conjugated at the 3’-end of the sense strand with mono galactose or mannose-6-
phosphate unit with the aid of a PEG linker containing a cleavable disulfide linkage 
(Fig. 10). The siRNA conjugates were studied for targeted delivery and gene silencing 
in vitro, in hepatocytes and hepatic stellate cell.117 In another study, GalNAc118 and 
galactosylated119 peptide nucleic acid (PNA) conjugates have also been efficiently 
targeted to rat liver.   
Scope of GalNAc cluster-ONs conjugates has not only remained limited to academic 
research but also has been of interest for pharmaceutical industries. Alnylam Inc. 
(MA, USA) has been developing siRNA based drugs. On support synthesis for a 
triantennary GalNAc cluster tethered to the 3’-terminus of the sense strand of the 
siRNA has been developed, and the conjugate has been applied to targeting to 
hepatocytes and shown to elicit efficient gene silencing in vitro and in vivo. 
Furthermore, these GalNAc-siRNA conjugates have been advanced for subcutaneous 
(SC) injection; preclinical trials showed significant improvement in tissue-specific 
delivery and efficacy compared to intravenous (IV) administration.112 Transthyretin 
(TTR) mRNA targeting GalNAc-siRNA conjugate has been observed to decrease of 
the level of TTR protein in blood in early human samples for the treatment of 
amyloidosis.120 Furthermore, GalNAc-siRNA conjugates also have been tested 
against hemophilia A and B for an RNAi mediated silencing of antithrombin III, a 
hemostasis regulatory protein.121  
 Introduction 27 
 
Figure 10. Galactose/GalNAc ON clusters 
IONIS Inc. (formerly known as ISIS Inc. CA, USA) has also been involved in developing 
antisense ON drugs, utilizing GalNAc-ASOs conjugate strategy. Recent results on 5’-
terminus conjugated GalNAc-ASOs showed 10 fold enhancement in silencing potency 
of second-generation gapmer ASOs in mouse liver.122 Furthermore, 5’–tethered 
GalNAc-ASO conjugates showed more potent in cell studies and animal studies as 
compared to 3’–tethered GalNAc-ASO conjugates. In case of 5’–GalNAc-ASOs cluster, 
the carbohydrate moieties were metabolized more rapidly and cleanly than 3’-conjugate, 
liberating active ASO in cytosol of hepatocytes.123 Very recently, extensive Structure 
Activity Relationship (SAR) study of GalNAc-ASO clusters has been published.124 In 
addition, Arrowhead Research Corporation (CA, USA) has  been developing the 
GalNAc-endosomolytic polymer-siRNA conjugates  targeting to the hepatocytes by 
dynamic polyconjugates siRNA delivery; siRNA is tethered to the polybutyl aminovinyl 
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ether polymer, which is masked with PEG chains, and GalNAc attached by a 
dialkylmaleic acid linker provides productive endosomal escape properties.125 
There has been high demand for finding new strategies for targeting and delivering ONs 
drug beyond the liver (ASGPR) target. For example, some of the cancer cell types 
overexpress receptors, which could be targeted specifically by either oligomeric or 
multivalent glyconjugate with ONs drugs. Recent studies on labelled glucose-ONs 
conjugates has demonstrated cell surface absorption and internalization via GLUT 
receptor mediated endocytosis (Fig. 11).126,127 Glucose molecule is very vital in cell 
metabolism and it is transported by glucose transporter proteins present in wide range of 
mammalian cells. In this study it has been noticed that longer spacer (15 to 18 atoms) 
were taken up more efficiently in cells than shorter ones (4 atoms) and surprisingly, 
tetravalent glucose ON conjugates did not facilitate cell uptake.  
Finally, PNA conjugates of 6-aminoglucosamine ring (ring II) of aminoglycoside 
antibiotic neomycin B was efficiently internalized in human cells and well distributed in 
cytosol and nucleus without trapping into nonproductive endosomes.128 Internalized 
PNA conjugates exhibited very high specificity towards target and resulted in vitro 
robust inhibition of Tat mediated transactivation of HIV-1 LTR transcription. 
  
Figure 11.  Glucose-ON Conjugates and PNA- aminoglycoside conjugate 
1.8 Oligonucleotide conjugation strategies 
Synthesis of ON chain is classically performed on a controlled pore glass resin (CPG) 
solid support, using an automated DNA/RNA synthesizer and standard phosphoramidite 
coupling protocols.129 Sequences are typically assembled 3’→ 5’direction, and hence the 
5’-terminus is the obvious choice for conjugation. Different types of functionalities can 
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be attached to the 5’-hydroxyl group. 3’-End is another accessible site, but the chain 
assembly is then usually accomplished on a modified solid support bearing the desired 
conjugate group. It is also possible to assemble ON sequence in reverse manner, so that 
5’-terminus is attached to solid support and chain is grown in 5’→ 3’direction. Intrachain 
conjugation can be achieved, by making use of exposable hydroxyl groups of pre-
fabricated building blocks.130,131 Therefore, various cell targeting ligands/moieties can 
be tethered to different sites on ON chains, as long as they do not too severely affect 
base pairing, biophysical properties and pharmacological activity.  
Strategies for synthesis of ON conjugates fall in to two main types: i) Solution phase 
conjugation of the pre-fabricated and purified ON and conjugate group, each bearing an 
appropriate functionality required for coupling. In an optimal case, the coupling is so 
efficient that stoichiometric amount of ON and conjugate group can be used, which 
markedly simplifies the purification. ii) Solid phase synthesis, in which entire conjugate 
is assembled on single support. The assembly can be carried out by either using 
prefabricated building blocks or by stepwise assembling the conjugate group prior to or 
after the ON synthesis. Solid phase conjugation strategy allows the use of excess amount 
of reagents for pushing the reaction towards completion and conjugates are easily 
purified in the end by washing with solvents. However, solution phase conjugation is the 
method of choice in some cases, for instance when the conjugate moiety is unstable 
under ammonolytic conditions or it is synthetically so-challenging that usage of an 
excess amount for conjugation is not reasonable.111,131,132 
 Covalent linkages in oligonucleotide conjugates 
Several types of reversible and irreversible linkages have been exploited in ON 
conjugation chemistry. Recently developed bioorthogonal conjugation approaches have 
received special attention. These post-synthetic conjugation methods can be efficiently 
utilized in both - solid supported as well as in solution phase synthesis. Some of the most 
commonly used covalent linkages are briefly described (Fig. 12).131 Naturally, amine 
groups have been used for amide bond formation by reacting with activated carboxylic 
group, while thiourea linkage are formed when amine attacks on isocyanate group. 
Aldehyde having electron deficient carbonyl center reacts quickly with nucleophilic 
amine, hydrazine, and aminooxy functional groups to produce imines, hydrazone and 
oxime linkages, respectively.  
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Figure 12. Common linkage types used for ON conjugations. 
Among these, amine linkages are obtained from imines by reductive amination. There 
has been mounting interest for the use of sulfur containing cleavable linkage such as 
disulfides in ON conjugates.133 Disulfides are linked to ONs in such manner that under 
reductive environment in cytosol, it liberates ONs, which may improve the 
pharmacological properties.  Synthesis of disulfide linkages can be obtained by reaction 
of free thiol group with active thiol. Similarly, thioethers and thiazolidines that undergo 
cleavage in acidic medium have been utilized in ON conjugation.71 
Stable trizole linkage is obtained by recently developed click chemistry.134 Click reaction 
usually works with high specificity, and efficiency. It is also known as Huisgen 1,3-
dipolar cycloaddition,:  a Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC), forms a 
triazole linkage in aqueous solvents at room temperature. However, removal of copper 
from the reaction mixture is challenging, traces of copper remained along with 
conjugates may be cytotoxic in biological assays. As an alternative, recently copper free 
click reactions have recently been developed by using strained cyclooctyne derivatives, 
which reacts with azide moiety very efficiently, without any catalyst and the reaction 
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can be performed in aqueous medium.135,136Similarly, nitrone moiety is reacted with 
strained cycloocyne derivative to obtain N-alkylated isoxazolines linked ON 
conjugates.137 In addition, classical Diels-Alder cycloaddition reaction and Staudinger 
ligations also has been performed in ON conjugate synthesis.138,139 In addition, the length 
of attached linker is crucial in conjugation reactions and it may influence the 
pharmacokinetics of ON conjugates. Usually long chain linkers are preferred in 
preparation of ON conjugates. However alkyl chains are lipophilic in nature, in some 
instances they are less soluble in aqueous medium, and may forms aggregation. Hence, 
PEG linkers of about 8 to 10 atoms are used as an alternative.140 
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2. AIMS OF THE THESIS 
Over three decades, there has been mounting interest for the applications of potent ONs 
as a novel class of therapeutics. However, several biological barriers are inevitably 
required to pass and improve ONs properties more like drugs. A major hurdle, which 
remains to be overcome, is the efficient delivery of these charged macromolecules into 
cells across the cell membrane. In general, cellular uptake of naked ONs is inefficient 
and only a small number of ON molecules actually gain entry to the cell. Traditionally, 
in cell culture studies, commercially available transfecting agents, a positively charged 
cationic lipids has been used by forming complexes with negatively charged ONs. 
However, the successful in vivo applications of the single stranded antisense ONs or 
antigomirs or double stranded siRNAs in the animal models and clinic obviously require 
improvements in cellular targeting, intracellular delivery and pharmacological 
properties.  
The covalent chemical conjugation approach may possibly alter the in vivo bio-
distribution and possibly cellular uptake. This expectedly leads to enhanced 
internalization of the conjugate by receptor-mediated endocytosis to facilitate the 
cellular uptake directly in cytoplasm for pharmacological effects. This approach in 
general, is aimed at facilitating targeted cellular uptake of both single stranded 
antagomirs and double stranded siRNAs.  
The whole-body distribution of the conjugates in rats has been followed by positron 
emission tomography (PET). The 68Ga-labeled ONs conjugated with different receptor 
targeting moieties were used as imaging agents for PET studies. These studies included 
clarification of the metabolic fate of 68Ga-ONs in healthy rats and in diseased rat models, 
which also elucidated the in vivo specificity of ONs. The ONs were efficiently labeled 
by binding 68Ga, a PET tracer, to a 3´-terminal conjugated 1,4,7-Triazacyclononane-
1,4,7-triyl)triacetic acid (NOTA) ligand. This offered a powerful tool for determination 
of pharmacokinetics and tissue distribution of antagomir molecules, and allowed in vivo 
quantification of ON pharmacokinetics and bio-distribution data in rats.  
The present thesis is aimed at clarifying the applicability of different receptor-based 
strategies for cell-specific targeting of ON drugs. The conjugate moieties, in the form of 
clustered/linear oligomeric carbohydrates and bisphosphonate derivative, may possibly 
enrich the ON conjugate on the surface of a certain organ/cell-type. i) Galactose cluster 
ON conjugates have been successfully emerged for in vivo targeting of liver.112,123  
Combination of PET technique and galactose cluster ON conjugation approach, may 
potentially provide rational quantitative data for bio-distribution, which could be an 
expedient for the development of ON therapeutics. ii) Hyaluronic Acid (HA)-CD44 
interactions,141 may possibly offer CD44 receptors targeting by HA-ON conjugates for 
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therapeutic applications. Enrichment of HA ligands with conjugated ONs on the CD44 
expressing cell surface could lead to enhanced internalization by endocytosis and 
eventually also to increase concentration in the cytoplasm. iii) Bisphosphonates (BPs) 
are the attractive moiety for the targeting of bone tissues.142-144 The efficacy of BPs is 
based on their remarkable tendency to localize rapidly on the bone surface after being 
administered.145,146 Therefore, by linking of an ONs to BPs, selective targeting to bone 
tissue can be achieved. iv) Porphyrins recently have been emerged as a bifunctional 
agent in tumor imaging and photo dynamic therapy (PDT).147 Carbohydrates-conjugated 
porphyrin based photosensitizers have attracted particular interest, since the sugar 
moiety may offer selective targeting of cancer cells via host lectin binding.148 Porphyrin 
core forms stable chelation with radiometals, which makes porphyrins good probes for 
(PET) studies. 149 Hence, immobilization of porphyrins to a solid support may allow 
simple and even automated tailoring of the conjugate part that facilitates, in particular, 
screening of new photosensitizers and PET-tracers. 
The aims of the thesis are summarized as follows: 
 Synthesis of 68Ga-labeled galactose cluster ON conjugates and their in vivo PET 
imaging studies in healthy rats.  
 Synthesis of hyaluronic acid ON conjugates and their in vivo PET imaging 
studies in healthy and myocardial infarction rats. 
 Synthesis of bisphosphonate ON conjugates and their in vivo PET imaging 
studies in healthy rats. 
 Preparation of solid supported porphyrins for the straightforward synthesis of 
porphyrin biomolecules (particularly ONs and oligosaccharides) conjugates. 
 Results and Discussion 35 
3. RESULTS AND DISCUSSION 
3.1 Therapeutic significance of anti-miR-15b and anti-miR-21 
The miR-15, microRNA precursor family comprises small noncoding RNAs such as 
miR-15a, miR-15b, miR-16-1, miR-16-2, miR-497 and miR-195. It has been suggested 
that, miR-15b is involved in hepatocyte apoptosis.150, 151 In addition, silencing of miR-
15b protects against cardiac ischemic injury.152 Therefore, inhibition of miR-15b has 
emerged as a potential therapeutic target in liver and heart. It was recently found that, 
many types of cancer and solid tumours showed overexpression of miR-21. Several 
studies exhibited that overexpression of miR-21 results in suppression of vital tumour 
suppressing genes, like PTEN, tropomyosin 1 (TPM1), and programmed cell death 
protein 4 (PDCD4). Hence, inhibition of miR-21 via antagomir approach has emerged 
as a promising therapeutic approach to combat cancer.153  
3.2 Positron emission tomography (PET) 
PET is a non-invasive nuclear imaging technique, which has been advanced for 
quantitative visualization of various radiolabeled biomolecules, including ONs with high 
imaging contrast. Spontaneous decay of radioactive isotope emits high energy gamma 
ray photons, which are detected during imaging process. Mechanistically, nucleus of 
radioactive isotope undergoes beta plus (β+) decay, because of unstable nuclear system. 
Proton is converted into a neutron, as well as positron, and an electron neutrino. Positron 
and electron annihilation, produces two gamma ray photons, travelling in (180o) opposite 
direction. Commonly used radionuclide isotopes in PET imaging includes, 18F (t1/2 = 
109.8 min), 68Ga (t1/2 = 68 min), and 64Cu (t1/2 = 12.7 h).  For instance, 68Ga radiometal 
has been complexed with an appropriate ligands like NOTA, or DOTA, which are 
covalently linked to the ONs.154,155 
3.3 Synthesis of 3’-NOTA-conjugated oligonucleotides using 
solid supported chelator strategy (SSCS) 
NOTA modified controlled pore glass (CPG) support (2) allows preparation of 3’-
radiometallated ONs and subsequent derivatization of the 5’-end with a conjugate group. 
Support 2 was prepared according to a previously reported method. 155 The trimethyl 
ester precursor of (1,4,7-triazacyclononane-1,4,7-triyl)triacetic acid 1, bearing a 4,4´-
dimethoxytrityl protected 4-(4-hydroxybutoxy)phenyl side arm on one of the acetic acid 
moieties,  was immobilized to a long chain alkyl amine derived LCAA-CPG with the 
aid of an ester linker (Scheme 1). A 22-mer 2’-O-methyl oligoribonucleotides such as 
anti-miR-15b (5’-UGU AAA CCA UGA UGU GCU GCU A-3’), anti-miR-21 (5’-AUC 
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GAA UAG UCU GAC UAC AAC U-3’) and T6 sequences were assembled on support 
2 by automated RNA-synthesis (1.0 μmol scale) via phosphoramidite chemistry. The ON 
conjugates were released from the support by two-step cleavage protocol: (i) the supports 
in micro-centrifuge tubes were first treated with 0.1 mol L-1 aq. NaOH for 3 h at 55ºC 
and the suspensions were neutralized by addition of 1.0 mol L-1 aqueous ammonium 
chloride. (ii) Overnight incubation in concentrated aqueous ammonia at 55ºC was then 
performed (Scheme 11). Otherwise, direct global hydrolysis using conc. ammonia may 
form side products containing amide bond instead of desired free carboxylic acid/salt 
functions on NOTA chelator. The product was purified by RP HPLC and characterized 
by ESI-MS.  
 
Scheme 1. Reagents and conditions: i) NaO(CH2)5OH, in pentane-1,5-diol, MeCN, ii) 
succinanhydride, DMAP, pyridine, iii) LCAA-CPG, PyBOP, DMAP, DMF, iv) Ac2O, 2,6-
lutidine, N-methylimidazol, THF, v) An automated ON synthesis via phosphoramidite chemistry, 
vi) (1) 0.1 mol L-1 aq NaOH, 3h at 55ºC (2) conc. aq NH3, overnight at 55ºC. 
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3.4 Synthesis of 5’-galactose cluster, 3’-NOTA oligonucleotide-
conjugates 
Non-nucleosidic phosphoramidite building blocks were attached to the 5’-terminus to 
allow synthesis of glyco-ON conjugates. 2-Cyanoethyl (methyl 2,3,4-tri-O-acetyl-α-D-
galactopyranoside-6-O-yl)-N,N-diisopropyl phosphoramidite 9 was prepared by 
phosphitylation of methyl 2,3,4-tri-O-acetyl-α-D-galactopyranoside with 2-cyanoethyl 
N,N-diisopropylphosphoramidochloridite. On support coupling of 9 to the 5’-terminus 
of the ON gave support 15. 3’-NOTA modified ONs bearing three or seven galactose 
residues were obtained by solid-supported oximation (Scheme 3 and 4). An aminoxy 
group is highly nucleophilic towards carbonyl moiety and the oxime linkage resulted is 
stable over wide pH range. Non-nucleosidic phosphoramidites such as, 2-cyanoethyl-5-
(phthaliimidooxy)pent-1-yl-N,N-diisopropylphosphoramidite156 10  and 2-cyanoethyl-3-
(4,4’-dimethoxytrityloxy)-2,2-bis{3-[(phthaliimidooxy)propyl]carbamoyl}propyl-N,N-
diisopropylphosphoramidite, 11 were synthesized as per previous reports157 and their 
coupling to the 5’-terminus of ONs, gave supports 17 and 20, respectively. 
 
Figure. 13 Structures of Non-nucleosidic phosphoramidite building blocks and trigalactose 
scaffold. 
Trigalactose scaffold 12 bearing a benzaldehyde group was synthesized by Cu(I) 
promoted click reaction of 3-azidopropyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside158 
13 with previously reported 4-(tri-O-propargylpentaerythrityloxy)benzaldehyde159 14 
(Scheme 2). Pthaloyl protection on conjugate 17 was removed by treatment with 
hydrazinium acetate in pyridine. Trigalactose cluster bearing a benzaldehyde group was 
reacted with the exposed aminoxy group of 17 gave oxime linked on support conjugate 
18. Similarly, to obtain a heptagalactose clustered ON, support 3 was first phosphitylated 
with 11, detritylated and subjected to treatment with 9 to get support 20. The branching 
unit was capped in this manner in order to avoid cleavage via retro aldol condensation. 
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Afterward, both pthaloyl groups were removed by hydrazinium acetate treatment in 
pyridine and the exposed aminoxy units were subjected to oximation with trigalactose 
cluster 12 to afford support 21. Finally, all supports 15, 18, and 21 were deprotected via 
previously reported two step protocols.155 The desired conjugates 16, 19 and 22 were 
purified by RP HPLC and characterized by MS (ESI-TOF) (Table 1). An example of 
HPLC chromatograms and MS (ESI-TOF) spectra of the products (homogenized hepta-
galactose-ON cluster conjugate) is depicted in figure 13. 
 
Scheme 2. Synthesis of the trivalent galactose cluster. Conditions: (i) CuSO4, sodium ascorbate, 
H2O, dioxane 
 
Scheme 1. i) 9, phosphoramidite coupling, ii) (1) 0.1 mol L-1 aq NaOH, 3h at 55ºC (2) conc. aq 
NH3, overnight at 55ºC. 
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Scheme 3. Reaction and conditions: i) phosphoramidite coupling with 10 on automated ON 
synthesizer,  ii) hydrazinium acetate, AcOH, pyridine, iii) 0.17 mol L-1 of 12 in MeCN, overnight 
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Scheme 4. Reaction and conditions: i) sequential phosphoramidite coupling with 11 and 9 on 
automated ON synthesizer, ii) hydrazinium acetate, AcOH, pyridine, iii) 0.17 mol L-1 of 12 in 
MeCN, overnight at r.t., iv) (1) 0.1 mol L-1 aq NaOH, 3h at 55ºC (2) conc. aq NH3, overnight at 
55ºC. 
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Table 1. MS (ESI-TOF) data the conjugates  
entry ON conjugate observed average 
molecular massa  
calculated average 
molecular mass 
1 22 10719.5 10719.0 
2 19 9146.8 9148.6 
3 16 8097.1 8097.4 
aCalculated from the most intensive isotope combination at [(M-11H+K)/10]-10 
    
Figure 13. RP HPLC chromatogram and MS (ESI-TOF) spectrum of the homogenized hepta-
galactose-ON conjugate. RP HPLC conditions: A gradient from 0% to 35% MeCN in 50 mmol 
L-1 aqueous NH4OAc over 35 min (flow rate 1 mL min-1, detection at 260 nm) on a Thermo ODS 
Hypersil column (150 × 4.6 mm, 5µm). 
3.5 Hyaluronic acid -oligonucleotide conjugates 
Hyaluronic acid (Hyaluronan, HA) is the only non-sulfated member of linear 
glycosaminoglycan polysaccharide family [chondroitin sulfate (CS), heparan sulfates 
(HS), dermatan sulfate (DS), keratan sulfate (KS)]. HA is composed of β-1,3-linked 
repeating disaccharide unit of 2-acetamido-2-deoxy-D-glucose-β-(1,4)-D-glucuronic 
acid. HA is a major component of extracellular matrix, which is essential for structural 
organ stability, tissue organization and cell growth. HA of size 6-8 monosaccharides has 
binding affinity to specific cell surface transmembrane glycoprotein receptor such as 
CD44 (cluster of differentiation 44).160 In many cancer types, CD44 is up-regulated in 
active high-affinity state, which binds and internalize the HA ligand by endocytosis. 
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However, in normal primary cells, CD44 is endogenously expressed in low level and 
pre-activation of CD44 receptor is required for binding of HA ligand.   
 Synthesis of hyaluronic acid building blocks 
Syntheses of HA tetramer and hexamer were carried out by convergent glycosylation 
using TMSOTf as an activator. Appropriately protected glucosamine glycosyl acceptor 
28 was synthesized as per previously reported method,161 starting from commercially 
available β-D-glucosamine hydrochloride 23. (Scheme 5) The 2-amino position was 
protected with the N-trichloroacetyl group (N-TCA), a well-known participating group 
for stereoselective formation of the required 1,2–trans glyosidic linkage. A difficulty 
associated with the use of 2-deoxy-2-trichloroacetamido glycosyl donor is the formation 
of stable trichlorooxazoline side products.162,163 In addition, deprotection of multiple N-
TCA groups from oligosaccharide via global hydrolysis conditions can also be 
challenging. Alternatively used method, radical reduction with Zn/AcOH or 
tributylstannane/AIBN may produce undesirable mono- and dichloroacetamido 
intermediates.164,165,166 We decided to use conc. ammonia treatment for N-TCA 
deprotection step. Tetraacetylated N-TCA glucosamine 24 was treated with hydrazinium 
acetate for selective removal of acetate group at the anomeric position to afford 
hemiacetal 25. tert-Butydimethylsilyl group was employed at the anomeric center as a 
temporary protecting group 26. 4,6-O-Benzylidene protected glycosyl acceptor 28 was 
obtained by removal of acetyl groups with methoxide ion catalyzed transesterification in 
MeOH, followed by acid-catalyzed transacetalization with benzaldehyde dimethyl 
acetal. To obtain glucuronate donor 39, previously reported methods were used, 167 as 
outlined in Scheme 6. Commercially available peracetylated glucose 29 was converted 
to 1-phenylthio tetraacetate glucose 30 by glycosylation reaction with thiophenol, using 

















































Scheme 5. Reaction conditions: i) Trichloroacetyl chloride, NaHCO3, H2O, rt, 16h; ii) Ac2O, 
Pyridine, 0oC to rt, overnight; iii) H2NNH2 AcOH, DMF, rt, 3h; iv) TBSCl, Imidazole, DMF, rt, 
4h; v) 0.1 M NaOMe, MeOH, rt, 3h; vi) PhCH(OMe)2, p-TSA, CH3CN, rt, 1 h. 





































































Scheme 6. Reaction conditions: i) PhSH, BF3·Et2O, CH2Cl2, rt, 5h; ii) 0.1 M NaOMe, MeOH, rt, 
3h; iii) PhCH(OMe)2, p-TSA, CH3CN, rt, 1h; iv) PhCOCl, DMAP, pyridine, 0oC to rt, 1h; v) p-
TSA, CH2Cl2, MeOH, rt; vi) TEMPO, BAIB, CH2Cl2, H2O, rt, 45 min; vii) MeI, K2CO3, DMF, 
rt; viii) levulinic acid, DCC, DMAP, CH2Cl2, rt; ix) NIS, Tf2O, CH2Cl2, H2O, rt; x) CCl3CN, 
DBU, CH2Cl2, 0oC to rt, 2.5 h. 
Acetyl groups were removed by transesterification with sodium methoxide in methanol, 
and resultant tetraol 31 was converted to 4,6-O- benzylidene protected glucose 32. The 
remaining C-2 and C-3 hydroxy groups were benzoylated and the 4,6-O-benzylidene 
protection was removed under acidic condition to obtain 34. The 6-OH was oxidized 
regioselectively by free radical mediated TEMPO/BAIB approach to afford the 
corresponding glucuronic acid 35. After esterification of the carboxy function, 4-OH was 
protected by levulinyl group and finally trichloroacetimidate glucuronate donor 39 was 
obtained by hydrolysis of 1-phenylthio glucuronate methyl ester followed by DBU 
catalyzed acetimidate formation.  
 
Scheme 7. Reaction conditions: i) TMSOTf, CH2Cl2, 0 oC, 45 min; ii) Et3N 3HF, THF, rt; iii) 
CCl3CN, DBU, CH2Cl2, 0 oC, 30 min; iv) 3-azidopropanol, TMSOTf, CH2Cl2, 0 oC; v) 
H2NNH2.H2O: AcOH, pyridine, rt, 15 min. 
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 Synthesis of functionalized hyaluronic acid oligosaccharides 
TMSOTf-catalyzed glycosidation between acceptor 28 and donor 39 in CH2Cl2 afforded 
the β-glycoside 40 (Scheme 7). Desilylation of 40 and subsequent treatment of the 
hemiacetal with trichloroacetonitrile in the presence of catalytic amount of DBU gave 
disaccharide trichloroacetimidate donor 42. Anomeric functionalization with propyl azide 
was achieved by TMSOTf catalyzed condensation of disaccharide donor 42 with 1,3-
azidopropanol in CH2Cl2. 4’-Levulinoyl protection of 43 was removed by hydrazine 
hydrate treatment to afford azide functionalized glycosyl disaccharide acceptor 44. The 
coupling reaction of disaccharide glycosyl donor 42 with disaccharide glycosyl acceptor 44 
as described above, afforded the HA tetrasaccharide derivative 45 (Scheme 8). Acidolytic 
removal of the benzylidene groups of compound 45 gave partially protected azido propyl 
functionalized HA tetramer 47. Similarly, hexasaccharide was obtained from glycosylation 
reaction with 42 and 46 and acidolytic removal of benzylidene protections gave partially 






















































































Scheme 8. Reaction conditions: i) TMSOTf, CH2Cl2, 0 oC, 45 min; ii) H2NNH2.H2O: AcOH, 
Pyridine, rt; iii) 42, TMSOTf, CH2Cl2, 0 oC, iv) p-TSA, CH2Cl2: MeOH, rt. 
 Synthesis of 5’-hyaluronan 3’-NOTA oligonucleotide-conjugates 
Anti-miR-15b and T6 were assembled on NOTA modified CPG support (2) as described 
earlier (Section 3.3). Commercially available 2-(bicyclo[6.1.0]non-4-yn-9-yl)ethyl 2-
cyanoethyl N,N-diisopropylphosphoramidite (BCN phosphoramidite) was then coupled 
at the 5’-end of the ONs (Scheme 9). ONs were released from NOTA-CPG support by 
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treatments with, aqueous alkali followed by concentrated ammonia.142 BCN-anti-miR-
15b-NOTA and BCN-T6 conjugates were purified by RP HPLC (Figure 14) and 
characterized by ESI-MS. (Table 2). BCN-anti-miR-15b-NOTA (50, 0.1 µmol) and 
BCN-T6 sequences (49, 0.1 µmol) could be virtually quantitatively conjugated with 
azide modified hyaluronic acid hexasaccharide (48, 0.2 µmol) and tetrasacharide (47, 
0.2 µmol) via copper-free strain promoted azide alkyne cycloaddition (SPAAC) in 
CH3CN:H2O (1:9, v/v, 100 µL), overnight at 55oC. 
 
Scheme 9. Reaction conditions: i) Automated ON synthesis by phosphoramidite coupling 
chemistry., ii) 48, MeCN-H2O (1:9, v/v), overnight at r.t., iii) 0.1 mol L-1 aq NaOH, 3h at 55°C, 
iv) conc. aq NH3, 5 days at 55°C, v) Ac2O, Et3N, H2O, CH3CN, 6h at r.t., vi) conc. aq NH3, 
overnight at 55°C. 
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Removal of remaining protecting groups of the HA conjugates was achieved by two 
steps: esters were first hydrolyzed in aq. NaOH and then concentrated ammonia was 
used to complete the removal of the trichloroacetyl groups from the glucosamine units 
(5 days at 55oC). Progress of the global deprotections was monitored by RP-HPLC 
(Figure 14) and ESI-MS. Acetylation of glucosamine units was carried out in aqueous 
medium with acetic anhydride and triethyl amine mixture. During acetylation step, 
nucleobases were also acetylated, and hence concentrated ammonia treatment was, once 
again, carried out to afford desired N-acetylated HA-ON conjugates. Homogeneity and 
identity of the ON conjugates were monitored by RP-HPLC (Figure 14), and ESI-MS 
(Table 2). Using a similar protocol, synthesis of HA hexamer-T6-NOTA 55 conjugates 
and HA tetramer-antimiR-15b-NOTA 57 were achieved. In addition, as a reference 
linear sugar-ON conjugate, azide modified peracetylated maltohexose 58 was 
conjugated with BCN-anti-miR-15b-NOTA 50, for this case deprotection needed only 
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Figure 14. RP HPLC chromatograms of post conjugation modifications. RP HPLC conditions: 
A gradient from 0% to 35% MeCN in 50 mmol L-1 aqueous NH4OAc over 25 min (flow rate 1 
mL min-1, detection at 260 nm) on a Thermo ODS Hypersil column (150 × 4.6 mm, 5µm). 
Table 2  
entry conjugate Calculated  molecular mass Observed molecular massa 
1 55 3755.9 3755.4 
2 56 9306.6 9306.5 
3 57 8927.3 8927.8 
4 59 9141.5 9142.2 
aObserved monoisotopic masses are calculated from [M-nH]n− and from the corresponding 
potassium and sodium adducts. 
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3.6 Bisphosphonate-oligonucleotide conjugates 
BPs are well-known bone seeking agents. They are analogs of the naturally occurring 
pyrophosphates (P-O-P), in which the oxygen is replaced by a methylene group, forming 
a P-C-P structure. The methylene group is usually substituted (R1 and R2, Figure 15). 
The P-C-P backbone and R2 group (preferably a hydroxyl group) have high affinity to 
bone mineral, hydroxyapatite. The R1 chain determines the potency of bisphosphonates 
to inhibit osteoclast-mediated bone resorption. Recently, bisphosphonates have been 
covalently linked to cytotoxic agents via a phosphate group.168,169 These high affinity 












60: R1 = N N
61: R1 = -CH2NH2
62: R1 = -(CH2)2NH2
R2 = OH
R2 = OH
R2 = OH  
Figure 15. Structures of bisphosphonate derivatives. 
 Synthesis of alendronate azide 
Alendronic acid/salt 62 is highly polar in nature, but still barely soluble in water or any 
polar solvents. Triethyl amine salts of alendronic acid was treated in water with 
imidazole-1-sulfonyl azide hydrogen chloride to result in a diazo transfer reaction 
(Scheme 10). Progress of the reaction was monitored by ESI-MS. The product could be 
enriched from the starting material by repeated washings and precipitations in DMF, 



























Scheme 10: Synthesis of alendronate azide 63, via diazo transfer reaction.  
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 Synthesis of 5’-alendronate 3’-NOTA oligonucleotide-conjugate 
An anti-miR-21 and T6 sequences were assembled on NOTA support as described earlier 
(Section 3.3). BCN phosphoramidite (0.1 molL-1) was introduced to the 5’-terminus of the 
support-bound anti-miR-21 and T6 sequences in the last coupling cycle. The ON conjugates 
were released from the support and deprotected by two-step cleavage protocol (Section 3.3). 
The product was purified by RP-HPLC. Crude alendronate azide (0.5 µmol) was coupled to 
5’-BCN-3’-NOTA-anti-miR-21 (0.2 µmol) by SPAAC conjugation in H2O (100 µL) 
overnight at 55οC. The product was purified by RP-HPLC, yielded 0.17 µmol (87%) of the 























66 ON = 2'-O-Me-anti-miR-21 
67 ON = T6
64 ON = 2'-O-Me-anti-miR-21 
65 ON = T6
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68 ON = 2'-O-Me-miR-21
69 ON = 2'-O-Me-miR-21
 



















Scheme 12: Duplex formation of 69 and 7. 
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In another approach, the alendronate and NOTA groups were introduced to separate ON 
strands (Scheme 12). Complementary sequence of anti-miR21-NOTA 7, i.e. miR-21 was 
assembled on standard 2’-O-Me support, bearing cyclooctyne modification at the 5’-
terminus and this sequence was released by ammonolytic conditions. Furthermore, 
SPAAC conjugation of alendronate azide 63 with 5’BCN-miR21 68, gave efficiently 
alendronate-miR-21 conjugate 69. Finally, these conjugates were purified by RP-HPLC 
and their authenticity was verified by MS (ESI-TOF) (Table 3).  
Table 3. MS (ESI-TOF) data of the alendronate-ON conjugates  
entry ON conjugate observed average 
molecular massa  
calculated average 
molecular mass 
1 67 2793.9 2793.6 
2 66 8309.6 8309.2 
3 
4 






aCalculated from the most intensive isotope combination at [(M-11H+K)/10]-10 
3.7 Solid-supported porphyrins  
Applicability of the solid supported porphyrins viz. 2-(1-Hexyloxyethyl)-2-devinyl 
pyropheophorbide-a (Photochlor, HPPH)170 and meso-tris(pyridin-4-yl)-(4-
carboxyphenyl) porphyrin (PyCPP)171 was demonstrated for the synthesis of various 
potential bioconjugates. HPPH is the commercially available effective photosensitizer 
that is currently in phase II clinical trials.172 Porphyrin shows high affinity to G-
quadruplexes,173 offering additional binding motives for targeting of ONs. Conjugate 76 
has a potential G-quadruplex-targeting ON sequence, complementary to single strand 
region of c-Myc, a cancer causing gene that induces transcription of growth-stimulating 
genes in many types of human cancer.174 Synthesis of dendritic galactose cluster 
conjugates of porphyrin 77-80 was also demonstrated. Galectins are galactose–binding 
lectins, overexpressed on breast cancer cells175 and melanomas.176 Dendritic galactose 
clusters of porphyrin may, hence, play vital roles as cancer cell specific targeting of 
photosensitizers in photodynamic therapy (PDT).177 
 Synthesis of solid-supported porphyrins 
For the synthesis of solid supported porphyrins (HPPH and PyCPP) (1R, 2S, 3R, 4R)-
2,3,4-trihydroxy-1-aminocyclopentane was utilized as a branching unit (Scheme 13). 
The amino group of compound 70 was trifluoroacetylated, the primary hydroxyl group 
(6-OH) 4, 4′-dimethoxytritylated and the amino group was then re-exposed by a 
hydrazine hydrate treatment. These three steps could be carried out in one pot to provide 
compound 71 in 70 % overall yield. HPPH and PyCPP were coupled quantitatively to 
71, via PyBOP-induced amide bond formation. Treatment of compound 72 and 73 with 
50 Results and Discussion  
succinic anhydride gave mixtures of mono- and disuccinate derivatives, which were 
coupled to LCAA-CPG support using PyBOP-promoted activation. Loadings of PyCPP 
and HPPH on the CPG support, determined by the DMTr-cation assay, were 20 μmolg−1 
and 23 μmol g−1 respectively. Finally, supports were subjected to treatment with acetic 





























72 R1 = A, 97%





74 R1 = A










 positions of 2' -OAc, and 3'- succinyl linkage
may be interchanged  
 
Scheme 13: Reagents and conditions: (i) MeOCOCF3, MeOH, Et3N; (ii) DMTrCl, 
pyridine; iii) NH2NH2·H2O, dioxane, iv) meso-tris(4-N-pyridyl)(4-
carboxyphenyl)porphyrin or HPPH, PyBOP, DIEA, DMSO-DMF (1:3, v/v); (v) Ac2O, 
DMAP, pyridine; (vi) KOH, H2O, DMF; (vii) succinic anhydride, DMAP, pyridine; (vi) 
LCAA-CPG, DIEA, PyBOP, DMF; (vii) Ac2O, 2,6-lutidine, N-methylimidazol, THF. 
 
 Phosphoramidite couplings using supports 
In order to prepare dendritic glyco-conjugates, commercially available  
phosphoramidite, trebler unit 76 was used for the synthesis of conjugate 80-83 (figure 
16). Cyanoethyl (methyl 2,3,4-tri-O-acetyl-α-D-galactopyranoside-6-O-yl)-N,N-
diisopropylphosphoramidite 9 was coupled to branched cores. Conjugation of 
porphyrins with ONs and dendritic galactose clusters (77−83) were accomplished by 
using supports 74 and 75 (0.5 µmol aliquots) on an automated DNA/RNA-synthesizer. 
Phosphoramidite coupling chemistry was used. Finally, the conjugate was released from 
the support by treatment with concentrated ammonia (2 h at 55 °C) and purified by RP 
HPLC. Crude RP HPLC profiles of conjugates (82 and 83) are shown in figure 17 and 
isolated yields were determined on the basis of porphyrin absorption in aqueous 
solutions. Authenticity of conjugates (77−83) was verified by MS (ESI-TOF) (Table 4).  
 Results and Discussion 51 
 Synthesis of hyaluronic acid-PyCPP-conjugate 
2-(Bicyclo[6.1.0]non-4-yn-9-yl)ethyl 2-cyanoethyl N,N-diisopropylphosphoramidite 
was coupled to support 74 and the cyclooctyne-modified porphyrin 84 released by 
concentrated ammonia. Azide functionalized HA hexamer 48 was subjected to SPAAC 
conjugation in solution with strained cyclooctyne functionalized porphyrins, after 
released from support by treatment with conc. ammonia. After the SPAAC-conjugation, 
the protecting group manipulation of the HA moiety was carried out as described above 
for ONs (Scheme 9). Finally, the desired HA conjugate 85 was obtained by RP-HPLC 




















































































































77 A a 2616.1 2615.3 58% 
78 B a 2591.2 2590.7 31% 
79 A b 3447.6 3446.8 40% 
80 A c 1930.6 1930.6 51% 
81 B c 1905.7  1905.7 36% 
82 A d 4585.6 4584.2 25% 
83 B d 4560.7 4559.3 23% 
84 A e 1016.4  1016.4 n.d.a 
85 A f 2256.2 2255.7 20% 
a(isolated yield not determined: n.d.). bThe observed molecular masses have been calculated from 
the most intensive isotope combination at [M-H]-1 (84), [(M-2H)/2]-2 (77-81 and 85) and [(M-
3H)/3]-3(82 and 83). 
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82 R1 = A




Figure 17. Example of RP HPLC profiles of crude product mixtures (82 and 83). RP HPLC 
conditions: An analytical column (C18, 250 × 4.6 mm, 5 µm), a gradient elution from 20 to 100% 
MeCN in H2O over 25 min, flow 1.0 mL min-1, detection at λ = 400 nm. 
3.8 PET imaging, bio-distribution, and pharmacokinetics 
 PET studies of galactose conjugates 
3.8.1.1 68Ga-radiolabeling of Gal-oligonucleotide conjugates 
For PET labeling, 68Ga is obtained in the form of [68Ga]Cl3 from a 68Ge/68Ga generator. 
Synthesized Gal-ON conjugates (22, 19 and 16), containing NOTA chelate were 
subjected to form 68Ga complex. The radiochemical purity of [68Ga]-chelated Gal-ON 
conjugates were determined by a RP radio-HPLC (Fig. 18). The radiochemical purity of 
Gal-ON conjugates was obtained as follows 22 (95%), 19 (97%) and 16 (95%). 
 
Figure 18. Radio-HPLC chromatograms of hepta Gal- anti-miR-15b -68Ga-NOTA, 22.  
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3.8.1.2 PET imaging of galactose cluster oligonucleotide conjugates 
PET images on figure 19 represented the bio-distributions of radiolabeled (68Ga) NOTA-
galactose-ON conjugates (22, 19 and 16) in healthy rats. Ex vivo data on figure 20 and 
Table 5, showed the radioactivity accumulations in liver, kidneys and urine in healthy 
rats. Figure 21 represented activity vs. time curve for liver, kidneys and urinary bladder. 
Seven galactose cluster ON conjugate 22, and three galactose cluster ON conjugate 19 
exhibited enhanced accumulation in liver. About, 8 fold enhancement in liver activity 
was observed with seven galactose cluster ON conjugate (Fig. 20), whereas 5-fold 
enhancement with three galactose cluster ON conjugates 19 as compared to non-
glycosylated ON conjugate 6. One galactose-ON conjugate 16 and non-glycosylated ON 
conjugate 6 showed similar liver activity. For conjugate 22, activity vs. time curve on 
figure 21 showed over 60 min steady activity level in liver. In case of conjugate 19, liver 
activity was slightly lower. One galactose 16 and non-glycosylated 6 ON conjugates 
exhibited low activity level in liver. Ex-vivo experiments on Table 5 depicted that, 
highest activity in kidney was observed for non-glycosylated ON conjugate, followed by 
one galactose ON conjugate. Surprisingly, seven galactose cluster ON conjugate 22 
showed low activity in kidneys, but high activity in urine. In principle, low kidney uptake 
should lead to low excretion into urine. However, this may be explained by metabolic 
cleavage of 22 that takes place in liver and release the PET tracer into urine.  
 
Figure 19. Maximum intensity projections of PET images. Liver (L) showed the highest 
radioactivity concentration with hepta-Gal-ON conjugate 22 kidneys (K) showed the highest 
radioactivity concentration with (none Gal) ON-conjugate 6 and the highest radioactivity 
concentration in the urinary bladder (B) was observed with conjugate 22. (PET images are mean 
presentations of all time frames of 60-min acquisition) 
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Figure 20. Ex vivo measured radioactivity accumulation data in rat liver, kidneys and urine  
 







 Results and Discussion 55 
 
 
Table 5. Ex vivo biodistribution of intravenously injected 68Ga labeled compounds in healthy 
rats 








Adrenal gland 0.10 ± 0.024 0.40 ± 0.30 0.12 ± 0.025 0.25 ± 0.069 
Blood 0.076 ± 0.031 0.090 ± 0.053 0.13 ± 0.052 0.34 ± 0.19 
Bone 0.16 ± 0.055 0.47 ± 0.25 0.27 ± 0.11 0.40 ± 0.18 
Bone marrow 0.43 ± 0.069 2.0 ± 1.1 0.46 ± 0.19 0.67 ± 0.054 
Brain 0.0044 ± 0.0013 0.0070 ± 0.0048 0.0057 ± 0.0018 0.018 ± 0.0035 
Brown adipose tissue 0.077 ± 0.019 0.11 ± 0.061 0.099 ± 0.053 0.21 ± 0.046 
Heart muscle 0.076 ± 0.019 0.11 ± 0.038 0.083 ± 0.032 0.18 ± 0.059 
Intestine 1.1 ± 0.76 0.24 ± 0.031 0.15 ± 0.031 0.22 ± 0.034 
Intestine (cleaned) 0.42 ± 0.18 0.44 ± 0.26 0.19 ± 0.065 0.38 ± 0.11 
Kidney 23 ± 3.2 103 ± 11 150 ± 39 180 ± 103 
Liver 13 ± 3.1 9.1 ± 3.5 1.2 ± 0.19 1.7 ± 0.71 
Lung 0.13 ± 0.04 0.53 ± 0.25 0.16 ± 0.058 0.37 ± 0.089 
Muscle 0.028 ± 0.013 0.032 ± 0.011 0.032 ± 0.014 0.070 ± 0.015 
Pancreas 0.16 ± 0.026 0.24 ± 0.095 0.15 ± 0.074 0.33 ± 0.071 
Plasma 0.13 ± 0.045 0.26 ± 0.17 0.20 ± 0.073 0.62 ± 0.32 
Salivary gland 0.20 ± 0.055 0.30 ± 0.087 0.19 ± 0.055 0.43 ± 0.094 
Skin 0.11 ± 0.038 0.19 ± 0.047 0.22 ± 0.092 0.29 ± 0.088 
Spleen 0.87 ± 0.46 2.1 ± 0.69 0.55 ± 0.11 0.86 ± 0.57 
Urine 28 ± 11 12 ± 4.0 9.0 ± 3.2 11 ± 2.8 
White adipose tissue 0.030 ± 0.0069 0.025 ± 0.0086 0.027 ± 0.0075 0.061 ± 0.015 
Results are expressed as standardized uptake values (mean ± SD) 
 
 PET studies of hyaluronic acid conjugates 
3.8.2.1 68Ga-radiolabeling of hyaluronic acid-oligonucleotide conjugates 
Radiolabeling with 68Ga for the ON conjugates were carried out as described earlier 
(Section 3.8.1.1). Radio-HPLC analysis, demonstrated the radiochemical purities of the 
conjugates. The observed radiochemical purities as follows: 96 ± 0.21 % (55), 94 ± 1.5 
% (56), 92 % (57), 89 % (59), 99 % (6), 95 ± 1.7 % (8) and 98 ± 0.049 % (NOTA alone). 
Representative radio-HPLC chromatogram is shown in figure 22. The specific 
radioactivity was 4.7 ± 2.1 MBq/nmol at the end of syntheses.  
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Figure 22. An example (68Ga-NOTA-HA-anti-miR-15b, 56) of radio-HPLC chromatograms.  
3.8.2.2 Whole-body bio-distribution kinetics of hyaluronic acid conjugates 
in healthy rats  
Figure 23 represented the in vivo PET images of 68Ga labeled HA-ON conjugates. Time-
activity curves of the distribution kinetics are represented in figure 24. Bio-distribution 
data obtained by ex vivo studies are showed in figure 25. High radioactivity 
accumulation was observed in urinary bladder, kidneys, liver, intestine, spleen and bone 
marrow. In general, the bio-distribution of the conjugates was found to be varied with 
ON sequences as well as sugar units. It was observed that, the kidney, bone marrow, 
salivary gland and liver uptakes of anti-miR-15b conjugates (56-59 and 6) were 
considerably higher (kidney: P ≤ 0.021, bone marrow: P ≤ 0.0044, salivary gland: P ≤ 
0.00048, liver: P ≤ 0.049) as compared to T6 conjugates (55 and 8). Among the 
conjugates of anti-miR-15b sequences (56-59 and 8), carbohydrate moieties exhibited 
variation in bio-distribution. HA-hexamer-anti-miR15b conjugate 56 showed highest 
bone marrow uptake, maltohexaose-anti-miR-15b conjugates 59 showed highest uptake 
in salivary gland. The intestine uptake of HA-hexamer-T6 conjugate 55 was seen higher 
compared to 56-59, 6 and 8. Conjugate of anti-miR-15b 6 was the highest in blood 
uptake. Although, HA-hexamer-T6 conjugate 55 showed lowest kidney uptake, higher 
activity in urine excretion was observed as compared to all other conjugates (P ≤ 0.031). 
In addition, the lung uptake for conjugate of HA-hexamer-T6 55 was considerably lower 
as compared to all other conjugates (P ≤ 0.010), and NOTA-68Ga complex only. 
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Figure 23. Representative whole-body coronal PET images of rats intravenously injected with 
68Ga-conjugates 55-59, 6, 8 and NOTA alone. Images are summation from 0 to 60 min after 
injection. Radioactivity accumulates in heart (Hr), liver (Lv), kidneys (Kd) and urinary bladder 
(Bl). The intestine (In) accumulation is observed with 55. 
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Figure 24. Time-activity curves of the distribution kinetics.  
3.8.2.3 Rats with myocardial infarction (MI) 
Feasibility of targeting miR-15b by HA ON conjugates 55 and 56 in MI rats has also 
been demonstrated (Fig. 26). Ex vivo bio-distribution of 55 and 56 are represented in 
Table 6. Figure 26A-C illustrated the autoradiograph, hematoxylin-eosin and CD44 
immunohistochemically staining of the heart left ventricle cross section in a rat with MI. 
Uptake of HA hexamer-T6-68Ga-NOTA 55 conjugate was significantly increased in the 
infarcted myocardium as compared with the remote non-infarcted areas and myocardium 
of sham-operated rats (Figure 26D). The infarction-to-remote ratio of conjugates of HA 
hexamer-T6-68Ga-NOTA 55 and HA hexamer-anti-miR-15b-68Ga-NOTA 56 were 4.2 ± 
0.75 (P = 0.008) and 1.1 ± 0.4 (P = 0.016), respectively (Figure 26D). Ex vivo gamma 
counting further confirmed the improved uptake of HA hexamer-T6-68Ga-NOTA 55 in 
the infarcted left ventricle (SUV 0.183 ± 0.003) compared to sham-operated control 
(0.100 ± 0.009, P = 0.006; Table 6). Immunohistochemistry showed CD44 positive cells 
within the infarcted area (Figure 26C) 
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Figure 25. Radioactivity concentration at 60 min after intravenous injection of 68Ga-conjugates 
55-59, 8, 6 and NOTA as measured ex vivo by gamma counting of excised tissues of healthy rats. 
Results are expressed as standardized uptake value (SUV, mean ± SD). 
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Figure 26. 55 (68Ga-NOTA-HA-T6) and 56 (68Ga-NOTA-HA-hexasaccharide-anti-miR-15b) in 
rat myocardial infarction. A) Autoradiograph showing focally increased uptake of 68Ga-NOTA-
HA-T6 in the anterolateral wall (arrow) of the left ventricle at 7 days after coronary occlusion and 
B) the same section stained with hematoxylin-eosin that shows an infarcted area in the 
anterolateral wall (arrow). C) High magnification photomicrograph of immunohistochemical 
staining shows CD44 positive cells (arrows) in the infarcted area (scale bar 50 μm). Radioactivity 
concentration expressed as D) photostimulated luminescence per square millimeter (PSL/mm2) 
and E) infarction-to-remote ratio in myocardial autoradiographs shows higher 55 (68Ga-NOTA-
HA-T6) uptake in the infarcted than in the remote non-infarcted area or in the myocardium of 
sham-operated rats. 
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Table 6. Ex vivo bio-distribution of 55 and 56 at 70 min after intravenous injection in rats studied 
at 7 days after myocardial infarction or in sham-operation, and in healthy controls 
        Compound 55                Compound 56 
Tissue MI (n = 2) Sham (n = 2) Healthy (n = 4)  MI (n = 4) Healthy (n = 4) 
Adrenal gland 0.10 ± 0.027 0.079 ± 0.018 0.071 ± 0.011         0.18 ±   
        0.013 
0.17 ± 0.0063 




0.063 ± 0.020         0.20 ±  
        0.040 
0.15 ± 0.017 
Blood 0.23 ± 0.023 0.19 ± 0.0027 0.19 ± 0.012         0.30 ± 0.053 0.17 ± 0.011 
Blood cells 0.18 ± 0.042 0.17 ± 0.012 0.14 ± 0.012         0.24 ± 0.058 0.090 ± 0.031 




0.035 ± 0.0082         0.56 ± 0.075 0.35 ± 0.053 
Bone marrow 0.043 ± 0.037 0.069 ± 
0.0075 
0.053 ± 0.014         1.2 ± 0.30 1.5 ± 0.20 




0.032 ± 0.011         0.40 ± 0.14 0.12 ± 0.038 






        0.014     
        ±0.0079 
0.011 ± 0.0074 
Heart left 
ventricle 
0.18 ± 0.0031 0.10 ± 0.0088 0.040 ± 0.0068         0.25 ± 0.015 0.16 ± 0.011 
Intestine (empty) 0.47 ± 0.12 0.32 ± 0.13 0.46 ± 0.22         0.30 ± 0.065 0.37 ± 0.051 
Intestine (full) 1.5 ± 1.2 0.42 ± 0.47 1.1 ± 0.42         0.35 ± 0.18 0.20 ± 0.011 
Kidney 3.0 ± 0.26 2.9 ± 0.77 1.9 ± 0.23         82 ± 2.4 160 ± 11 
Liver 0.41 ± 0.0041 0.41 ± 0.078 0.46 ± 0.040         1.9 ± 0.26 1.7 ± 0.077 
Lung 0.19 ± 0.0028 0.17 ± 0.0075 0.12 ± 0.020         0.34 ± 0.067 0.31 ± 0.030 
Pancreas 0.080 ± 0.063 0.071 ± 
0.0039 
0.063 ± 0.018         0.35 ± 0.070 0.38 ± 0.051 
Plasma 0.40 ± 0.070 0.36 ± 0.0078 0.31 ± 0.027         0.53 ± 0.12 0.37 ± 0.032 




0.060 ± 0.0059         0.48 ± 0.083 0.43 ± 0.035 




0.033 ± 0.011         0.085 ± 
0.013 
0.056 ± 0.0060 
Skin 0.20 ± 0.0024 0.14 ± 0.0012 0.11 ± 0.0082         0.32 ± 0.028 0.34 ± 0.028 
Spleen 0.29 ± 0.070 0.26 ± 0.069 0.27 ± 0.032         0.49 ± 0.085 0.66 ± 0.12 
Urine 480 ± 130 260 ± 29 240 ± 120          32 ± 3.4 21 ± 2.3 
WAT 0.048 ± 0.014 0.030 ± 
0.0050 
0.035 ± 0.031         0.099 ± 
0.024 
0.047 ± 0.013 
MI: rat with myocardial infarction; Sham: sham-operated rat; BAT: brown adipose tissue; WAT: 
white adipose tissue; Bonewbm: bone without bone marrow. Results are expressed as standardized 
uptake values (mean ± SD with two significant figures). 
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 PET studies of bisphosphonate conjugates 
3.8.3.1 68Ga-labling of bisphosphonate-oligonucleotide conjugates 
Surprisingly, initial attempts of 68Ga labeling for the conjugate 66 and 67 were 
unsuccessful (as per obtained radio HPLC purity), most likely due to metal binding 
properties of alendronate moiety, beside NOTA ligand. Recently, Holub et al. reported 
that, presence of chelating BP moiety may lead to slower formation of GaIII complex 
with NOTA owing to the strong out-of-cage binding. 178 Therefore, double stranded ON 
68Ga labeling approach has been utilized, in which NOTA conjugate of anti-miR-21 7 
was first subjected to 68Ga-chelation and later alendronate attached to complementary 
strand i.e. miR-21 sequence, allowed to form 68Ga–labeled ON duplex 69 and 7 (figure 
27A). Thermal stability of the double helix was determined, by UV-melting profile 
analysis, Tm = 88ºC, 7[69/71Ga] and 69, 0.2 M NaOAc and 0.05 M NaCl as a mimics for 
68Ga-labelling conditions (Fig. 27A). Radio-HPLC chromatograms of 7[68Ga] are 













a) Tm = 77oC
b) Tm = 88oC
T / oC           
Figure 27. A) UV-melting profiles of 7/69–double helix. Conditions: a) 2 µM of 69 in 10 mM 
sodium cacodylate and 0.1 M NaCl (pH 7.0), b) 2 µM of 7[69/71Ga] and 69, 0.2 M NaOAc and 
0.05 M NaCl (the 68Ga-labelling conditions mimicked). B) Radio–HPLC chromatograms of 
7[68Ga] + 69. 
3.8.3.2 Whole-body bio-distribution kinetics of bisphosphonate 
conjugates in healthy rats 
Targeting of bone tissues with 68Ga-labeled ON duplex bearing BP moiety was 
demonstrated with in vivo PET imaging followed by bio-distribution kinetics in healthy 
rats. 68Ga-labeled ON duplex 69/7 showed increased uptake in knees (Fig. 28). 
Comprehensive ex-vivo measurements exhibited, 40% increased bone accumulation of 
68Ga-labeled ON duplex 69/7, bone marrow radioactivity accumulation was increased 
for 7 [68Ga] alone. Single stranded 7[68Ga] exhibited higher uptake in kidneys, liver, 
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spleen, salivary glands, pancreas, lungs, heart and skin, as compared to uptakes of 68Ga-
labeled ON duplex 69/7 (Fig. 29). Moreover, radioactivity concentration in plasma was 
decreased and activity in urine was increased for 68Ga-labeled ON duplex 69/7 (Fig. 30). 
The stability of ON duplex 69/7 during circulation was verified by adding excess, 2 or 4 
equivalents of non-labeled complementary strand bearing BP moiety. Use of excess of 
69, in order to make sure intact hybridization, did not exhibited difference in distribution 
kinetics as seen in detailed statistical analysis Table 7. 
 
Figure 28. PET/CT images of healthy rats intravenously injected with 68Ga-ONs. Images are 
summation from 0-60 min post-injection and presented in the same color scale. A) 7[68Ga] alone, 
B) 7[68Ga] + 69 one equivalent C) 7[68Ga] + 69 two equivalents and D) 7[68Ga] + 69 four 
equivalents. SUV = standardized uptake value; Mx = maxilla bone; Md = mandible bone; Hr = 
heart; Lv = liver; Kd = kidney; Bl = urinary bladder; Ep = epiphysis bone.  
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Figure 29. Radioactivity concentration at 60 min after intravenous injection of 68Ga-labelled ONs 
as measured ex vivo by gamma counting of excised tissues of healthy rats. SUV, standardized 
uptake value. Error bars denote standard deviation (n = 4). 
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Figure 30. Radioactivity concentration as a function of time (time-activity curves) of the 
distribution kinetics of 68Ga-labeled ONs: SUV, standardized uptake value. Error bars denote 
standard deviation (n = 4). 
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0.0066 0.29 0.50 0.67 










0.0023 0.20 0.26 0.79 
Urine 34 ± 22 120 ± 
12 






0.0015 0.29 0.19 0.76 








0.35 0.87 0.19 0.46 0.12 0.50 
Results are expressed as standardized uptake values (mean ± SD, n = 4) and P values of Student’s t test, with 2 significant 
figures. A = 1[68Ga] alone; B = 1[68Ga] + 1 equivalent of 2; C = 1[68Ga] + 2 equivalents of 2; D = 1[68Ga] + 4 equivalents 
of 2; BAT, brown adipose tissue; WAT, white adipose tissue, * without bone marrow. 
 Results and Discussion 67 
 64Cu labeling and in vitro receptor affinity of hyaluronic acid-
PyCPP conjugate 
64Cu in the form of [64Cu]CuCl2 was produced via the 64Ni(p,n)64Cu nuclear reaction, as 
previously described.179 An efficient 64Cu labeling of HA-PyCPP conjugate 85 was 
demonstrated  (Fig. 31) in NH4+AcO- buffer at 60 °C for 20−30 min, without use of any 
stabilizing agents (e.g., ascorbic acid, ethanol). Vortex mixing in 1-octanol/water: logP 
(15[64Cu] =−1.73±0.11) gave the lipophilicity of the 64Cu labeling of HA-PyCPP 
conjugate. HA hexamer is the natural ligand for CD44 receptors, expressed on cancer 
cells including MDA-MB-231 and MCF-7 breast cancer.180 In vitro receptor affinity 
studies (Table 8) showed low radio localization in these tumor cells. It was observed that 
about only 10% radioactivity was seemed to be bound or internalized after 30 min. 
incubation with MDA-MB-231 cells.  
 
Figure 31. Conditions: (i) 64CuCl2, aq. 0.5 mol L-1 NH4OAc. (pH 5.5), 30 min at 60 °C. RP HPLC 
chromatograms (a) radio- and (b) UV-detector, λ = 400 nm, respectively. 
Table 8: Cell binding evaluation of 64Cu-labeled PyCPP–HA conjugate (85[64Cu]) with MDA-
MB-231 and MCF-7 tumor cell lines. 
Competitor (nM) 
MDA-MB-231  MCF-7 
30 min (n = 3) 60 min (n = 
2) 
120 min (n = 
2) 
 60 min (n = 2) 
0 10.4 ± 0.3 9.3 ± 0.9 10.4 ± 0.5  10.5 ± 0.6 
2 9.9 ± 1.0 8.7 ± 0.3 9.9 ± 0.3  9.6 ± 0.7 
20 9.6 ± 0.8 8.6 ± 0.2 8.7 ± 0.3  9.5 ± 0.3 
200 8.0 ± 0.6 7.0 ± 0.1 6.6 ± 0.2  7.9 ± 1.0 
 
Receptor binding properties of 15[64Cu] was determined from in vitro incubation 
experiments with two tumor cell lines in the presence of increasing concentration of 
unlabeled PyCPP-HA conjugate (15) as the competitor. Values are expressed as ratio 
(%) of cell-bound radioactivity to the applied total radioactivity (mean ± SD).  
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4. SUMMARY 
Galactose-ON conjugates comprising 5’-terminus modification with seven, three or one 
Gal units have been attached to the 3’-NOTA modified anti-miR-15b sequence via on-
support oximation approach. NOTA-CPG support was used for assembly of ON 
sequence by standard phosphoramidite chemistry. Liver hepatocytes targeting of the 
galactose–anti-miR-15b cluster conjugates (22, 19 and 16) was demonstrated by an in 
vivo PET imaging in healthy rats. Synthesized conjugates has been efficiently 
radiolabeled with 68Ga and their whole body bio-distribution kinetics was studied by 
PET techniques. The galactose unit is the natural ligand for asialoglycoprotein (ASGPR) 
receptors, overexpressed on liver hepatocytes. Significance of glycocluster effect was 
successfully demonstrated,68Ga labeled conjugates bearing seven galactose-ON 
conjugate 22 showed remarkably higher activity, approximately 8 fold increase in liver 
activity as compared to one or none galactose-ON conjugate. Whereas tri Gal-ON cluster 
also showed 5 fold increment in liver radioactivity compared to one or none Gal-ON 
conjugate. Consistent with enhanced liver accumulation, the heptavalent Gal-ON cluster 
conjugate 22 showed low radioactivity in kidney. Urine activity was, however, increased 
as compared to other Gal-ON conjugates. In summary, significant increment was 
observed in the liver uptake of the Gal-ON conjugates (22 > 19 > 16 ~ 6), most likely 
due to glycocluster effect for targeting of ASGPR in liver. Importantly, this study 
provided a rational quantitative data for liver targeting of ON drugs, which has been 
monitored by PET technique, possibly guide for development of ON therapeutics. It is 
also worth noting that a substantial proportion of the ON was taken into the liver, 
although an unmodified phosphodiester backbone was used. 
Hyaluronic acid oligosaccharides has been efficiently conjugated to 5’-terminus of the 
ON conjugates, e.g. HA-hexamer-T6 55, HA-hexamer-anti-miR-15b 56, and HA-
tetramer-anti-miR-15b 57. Synthesis of HA hexamer has been achieved from 
appropriately protected HA disaccharides units via trichloroacetimidate activated 
glycosylation method, and TMSOTf as a glycosylation activator. A copper free click, 
strain promoted azide alkyne cycloaddition (SPAAC) conjugation approach has been 
demonstrated with partially protected azide functionalized HA oligomers with 5’-
strained cyclooctyne modified anti-miR-15b sequence, bearing 3’-NOTA ligand. The 
critical deprotections of oligosaccharides including removal of trichloroacetyl amide 
functions was carried out by concentrated ammonia treatment. Synthesized HA-ONs 
conjugate have been subjected to efficient radiolabeling with 68Ga. The PET imaging in 
healthy rats exhibited whole body bio-distribution kinetics, radioactivity distribution was 
varied with ON parts (anti-miR-15b and T6) along with sugar groups (e.g. HA hexamer, 
HA tetramer, Maltohexaose, and without sugar unit).       
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In general, higher radioactivity was observed in kidney, bone marrow, salivary gland, 
and liver for anti-miR-15b conjugates, as compared to conjugates of T6. Among these 
68Ga labeled conjugates, HA-hexamer-T6 55 and HA-hexamer-anti-miR-15b 56 were 
demonstrated in rat disease model, myocardial infarction (CD44 positive cells). It was 
found that, HA hexamer mediated uptake of the conjugates 55 and 56 into CD44 cells, 
in the infarcted myocardium as compared with the remote non-infarcted areas and 
myocardium of sham-operated rats. The conjugate HA-hexamer-T6 55 showed 
infarction-to remote ratio 4.2 ± 0.75 (P = 0.008). Surprisingly, the conjugate HA-
hexamer-anti-miR-15b 56 showed only 1.1 ± 0.4 (P = 0.016). In general, HA conjugates 
of T6 sequence verified the HA-CD44 interactions/binding. This study requires further 
detailed evaluation of ON structure, i.e. backbone modifications, length and sequence.  
Bone targeting PET labeled bisphosphonate-ON conjugates has been employed in this 
study. Alendronate azide derivative was prepared via copper free, diazo-transfer 
reaction. Similar to previous conjugation approach, synthesized azide derivative of 
alendronate was subjected to SPAAC conjugation with cyclooctyne modified anti-miR-
21 sequence. However, the presence of both moieties, 5’-alendronate and 3’-NOTA on 
a single stranded ON chain, turned out to be challenging for 68Ga radiolabeling. Hence, 
double stranded ONs strategy, in which a complementary sequence, bearing 5’-
alendronate modified miR-21, was hybridized with anti-miR-21 containing 3’-NOTA 
ligand. Interestingly, duplex of conjugate 69 with 7 exhibited, approximately ca. 40% 
(SUV) increased radioactivity accumulations in knee monitored by PET/CT imaging and 
measured ex vivo experiments in rats.  
Solid supported porphyrins were utilized for synthesis of potential bioconjugates such 
as, porphyrin conjugates with ONs, and glycodendrimers. In this study, porphyrins 
(HPPH and PyCPP), applicable photosensitizers were efficiently coupled on (LCAA-
CPG) support and synthesis of porphyrin conjugates with various oligomeric 
biomolecules was demonstrated using standard automated phosphoramidite coupling 
chemistry. In addition, 64Cu radiolabeling of porphyrin conjugates, HA−porphyrin 85 
was also verified and also their affinity was demonstrated in CD44-expressing cancer 
cells. 
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5. EXPERIMENTAL 
5.1 General 
The syntheses of building blocks and ON conjugates are described in the original 
publications.  Synthesized novel compounds were characterized by 1H NMR, 13C NMR, 
(400 and 500 MHz) and ESI-MS methods when applicable. The ON sequences were 
prepared on an Applied Biosystems 392 DNA synthesizer as per standard oligo’s 
assembly protocol. Oligo conjugates were analyzed by RP-HPLC, a Thermo ODS 
Hypersil C18 (150 × 4.6 mm, 5 μm) analytical column and a Phenomenex Oligo-RP C18 
(250 × 10 mm, 5 μm) semi-preparative column, gradient elution from 0% to 40% MeCN 
in aqueous 0.1 mol L−1 Et3NH+ AcO−. The flow rates 1.0 mL min−1 for analytical column 
and 3.0 mL min−1 for semi-preparative column were used at detection wavelength 260 
nm.  
5.2 PET labeling 
The 68Ga labeling protocols for ON conjugates are also described in the original 
publications. 68Ga was achieved as a [68Ga]Cl3 from the 68Ge/68Ga generator (Eckert & 
Ziegler, Valencia, California, USA). The radiochemical purity of 68Ga-labeled ON 
conjugates were determined by a reversed phase high performance liquid 
chromatography coupled with an online radioactivity detector (radio-HPLC) on a 
μBondapak C18 column (3.9 × 150 mm, 125 Å, 10 μm; Waters, Ireland).  
5.3 Distribution kinetics 
Whole-body distribution kinetics was assessed over a 60 min dynamic PET imaging 
(High Resolution Research Tomograph, Siemens Medical Systems, Knoxville, TN, 
USA). The uptake was reported as a standardized uptake value (SUV), calculated as the 
radioactivity concentration of the ROI normalized with the injected radioactivity dose 
and animal weight., The radioactivity concentration of various tissue samples was 
measured ex vivo by gamma counter (1480 Wizard 3″, PerkinElmer/Wallac, Turku, 
Finland), instantly afterward PET imaging. 
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